Combination cancer immunotherapy and new immuno

Nature Reviews Drug Discovery
14, 561-584
DOI: 10.1038/nrd4591

Citation Report

#	Article	IF	Citations
1	Immunotherapy Not Working? Check Your Microbiota. Cancer Cell, 2015, 28, 687-689.	7.7	43
2	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
3	FDA approves first immunotherapy combo. Nature Reviews Drug Discovery, 2015, 14, 739-739.	21.5	15
4	Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. Vaccines, 2016, 4, 38.	2.1	20
5	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98
6	Tumor-targeted costimulation by using bi-specific aptamers. Cancer Cell & Microenvironment, 2016, 3, e1333.	0.8	1
7	Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget, 2016, 7, 30323-30335.	0.8	297
8	Current State of Immune-Based Therapies for Glioblastoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e132-e139.	1.8	13
9	Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics. Oncotarget, 2016, 7, 66003-66019.	0.8	87
10	Prognostic value of perioperative leukocyte count in resectable gastric cancer. World Journal of Gastroenterology, 2016, 22, 2818.	1.4	15
11	Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget, 2016, 7, 82889-82901.	0.8	155
12	Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. Journal of Immunology Research, 2016, 2016, 1-11.	0.9	32
13	Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination. Mediators of Inflammation, 2016, 2016, 1-12.	1.4	25
14	Dendritic-Tumor Fusion Cell-Based Cancer Vaccines. International Journal of Molecular Sciences, 2016, 17, 828.	1.8	56
15	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Frontiers in Cell and Developmental Biology, 2016, 4, 27.	1.8	107
16	Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines, 2016, 4, 8.	2.1	68
17	Starved and Asphyxiated: How Can CD8+ T Cells within a Tumor Microenvironment Prevent Tumor Progression. Frontiers in Immunology, 2016, 7, 32.	2.2	85
18	Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination. Frontiers in Immunology, 2016, 7, 345.	2.2	59

#	Article	IF	Citations
19	Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Frontiers in Oncology, 2016, 6, 152.	1.3	24
20	Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. International Journal of Molecular Sciences, 2016, 17, 790.	1.8	32
21	Chemo-Immunotherapy Using Lentinan for the Treatment of Gastric Cancer with Liver Metastases. Medical Sciences (Basel, Switzerland), 2016, 4, 8.	1.3	7
22	Recent Advances of Light-Mediated Theranostics. Theranostics, 2016, 6, 2439-2457.	4.6	171
23	High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. OncoTargets and Therapy, 2016, Volume 9, 6511-6518.	1.0	13
24	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget, 2016, 7, 17194-17211.	0.8	80
25	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy, 2016, 8, 821-837.	1.0	139
26	PDâ€L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. Journal of Cutaneous Pathology, 2016, 43, 663-670.	0.7	85
27	Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor Elimination. Cancer Immunology Research, 2016, 4, 766-778.	1.6	19
28	Recent advances in immunoâ€oncology and its application to urological cancers. BJU International, 2016, 118, 506-514.	1.3	12
29	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€“ associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	1.5	80
30	Wilmsâ€™ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy, 2016, 8, 1309-1320.	1.0	14
31	Immunomodulatory and Antitumor Effects of a Novel TLR7 Agonist Combined with Lapatinib. Scientific Reports, 2016, 6, 39598.	1.6	6
33	Monocytic myeloid-derived suppressor cells as a potent suppressor of tumor immunity in non-small cell lung cancer. Oncology Letters, 2016, 12, 4785-4794.	0.8	16
34	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 304-313.e6.	0.9	11
35	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Molecular Therapy, 2016, 24, 1150-1158.	3.7	114
36	Inflammatory Markers Have a Role in Renal Cell Carcinoma Prognosis. European Urology Focus, 2016, 2, 341-342.	1.6	6
37	Instability of Helios-deficient Tregs is associated with conversion to a T-effector phenotype and enhanced antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6248-6253.	3.3	138

#	Article	IF	Citations
38	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44, 989-1004.	6.6	1,538
39	Immunosuppressive activities of adenosine in cancer. Current Opinion in Pharmacology, 2016, 29, 7-16.	1.7	216
40	Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens. Antimicrobial Agents and Chemotherapy, 2016, 60, 4183-4196.	1.4	10
41	Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. Science China Life Sciences, 2016, 59, 349-359.	2.3	10
42	Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2646-54.	3.3	272
43	Emerging nanotechnologies for cancer immunotherapy. Experimental Biology and Medicine, 2016, 241, 1116-1126.	1.1	26
44	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
45	Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion. MAbs, 2016, 8, 905-915.	2.6	13
46	Introduction to a review series on advances in cell-based immune therapeutics in hematology. Blood, 2016, 127, 3293-3293.	0.6	2
47	Human Leukocyte Antigen (HLA) Peptides Derived from Tumor Antigens Induced by Inhibition of DNA Methylation for Development of Drug-facilitated Immunotherapy. Molecular and Cellular Proteomics, 2016, 15, 3058-3070.	2.5	62
48	Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. , 2016, 168, 98-112.		95
49	Promoter methylation of the immune checkpoint receptor PD-1 (PDCD1) is an independent prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. OncoImmunology, 2016, 5, e1221555.	2.1	43
50	T-cell immunometabolism against cancer. Cancer Letters, 2016, 382, 255-258.	3.2	49
51	Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer. American Journal of Clinical Pathology, 2016, 146, 496-502.	0.4	78
52	â€œThresholdâ€crossingâ€• A Useful Way to Establish the Counterfactual in Clinical Trials?. Clinical Pharmacology and Therapeutics, 2016, 100, 699-712.	2.3	61
53	Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope. Cancer Treatment Reviews, 2016, 50, 208-216.	3.4	19
54	Senescence of T Lymphocytes: Implications for Enhancing Human Immunity. Trends in Immunology, 2016, 37, 866-876.	2.9	208
55	Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy. ACS Nano, 2016, 10, 9227-9242.	7.3	36

#	Article	IF	Citations
56	Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood, 2016, 128, 1590-1603.	0.6	139
57	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
58	The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity, 2016, 45, 374-388.	6.6	504
59	Role of Clinical Pharmacology in the Development and Approval of Immunotherapies Targeting Immune Checkpoints. Clinical Pharmacology and Therapeutics, 2016, 100, 591-593.	2.3	1
60	Engineering nanoparticles to overcome barriers to immunotherapy. Bioengineering and Translational Medicine, 2016, 1, 47-62.	3.9	114
61	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of antiâ€cancer antibodies: IUPHAR Review 18. British Journal of Pharmacology, 2016, 173, 1407-1424.	2.7	56
62	Deciphering CD137 (4â€1BB) signaling in Tâ€cell costimulation for translation into successful cancer immunotherapy. European Journal of Immunology, 2016, 46, 513-522.	1.6	104
63	Janus face-like effects of Aurora B inhibition: antitumoral mode of action versus induction of aneuploid progeny. Carcinogenesis, 2016, 37, 993-1003.	1.3	10
64	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. Methods in Molecular Biology, 2016, 1458, 159-177.	0.4	7
65	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. Journal of Gastrointestinal Cancer, 2016, 47, 351-357.	0.6	8
66	Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Science Translational Medicine, 2016, 8, 352ra110.	5.8	163
67	Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates as ligands: Loading into nanocarriers and preliminary biological studies. Journal of Inorganic Biochemistry, 2016, 165, 159-169.	1.5	18
68	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. OncoImmunology, 2016, 5, e1232222.	2.1	48
69	In vivo amelioration of endogenous antitumor autoantibodies via low-dose P₄N through the LTA4H/activin A/BAFF pathway. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7798-E7807.	3.3	9
70	Channelling potassium to fight cancer. Nature, 2016, 537, 497-499.	13.7	34
71	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. Cell Reports, 2016, 16, 2829-2837.	2.9	331
73	Advances in immunotherapy for melanoma management. Human Vaccines and Immunotherapeutics, 2016, 12, 2501-2511.	1.4	15
74	Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362.	5.1	156

#	Article	IF	Citations
75	Foldable glycoprobes capable of fluorogenic crosslinking of biomacromolecules. Chemical Science, 2016, 7, 6325-6329.	3.7	32
76	Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity. OncoImmunology, 2016, 5, e1192740.	2.1	11
77	Efficacy of Tumor Vaccines and Cellular Immunotherapies in Nonâ€“Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2016, 34, 3204-3212.	0.8	46
78	Exploiting Nanocarriers for Combination Cancer Therapy. Fundamental Biomedical Technologies, 2016, , 375-402.	0.2	1
79	BTLA identifies dysfunctional PD-1-expressing CD4⁺ T cells in human hepatocellular carcinoma. OncoImmunology, 2016, 5, e1254855.	2.1	36
80	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
81	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein and Cell, 2016, 7, 866-877.	4.8	44
82	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. OncoImmunology, 2016, 5, e1249559.	2.1	51
83	Immune checkpoint inhibitors for cancer treatment. Archives of Pharmacal Research, 2016, 39, 1577-1587.	2.7	43
85	Immunotherapy in kidney cancer. Current Opinion in Urology, 2016, 26, 543-547.	0.9	25
86	Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL. Journal of Immunotherapy, 2016, 39, 321-328.	1.2	10
87	Cancer Immunotherapy: Selected Targets and Smallâ€Molecule Modulators. ChemMedChem, 2016, 11, 450-466.	1.6	99
88	Cytogenetic and immunohistochemical biomarker profiling of therapyâ€relevant factors in salivary gland carcinomas. Journal of Oral Pathology and Medicine, 2016, 45, 655-663.	1.4	10
89	Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27, and CD137: Implications for Cancer Immunotherapy. , 2016, , 59-78.		0
90	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology, 2016, 13, 420-431.	1.9	78
91	Novel Immunomodulatory Pathways in the Immunoglobulin Superfamily. , 2016, , 41-58.		0
92	FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). International Journal of Molecular Medicine, 2016, 38, 3-15.	1.8	306
94	Cellular Therapies: Gene Editing and Next-Gen CAR T Cells. , 2016, , 203-247.		1

#	Article	IF	Citations
95	Current status of immunotherapy. Japanese Journal of Clinical Oncology, 2016, 46, 191-203.	0.6	52
96	Myeloid cells in the tumor microenvironment: Role of adenosine. OncoImmunology, 2016, 5, e1108515.	2.1	45
97	Tumour-infiltrating lymphocytes in melanoma prognosis andÂcancerÂimmunotherapy. Pathology, 2016, 48, 177-187.	0.3	210
99	Hepatocellular carcinoma cell sensitivity to Vî³9Vî²2 T lymphocyte-mediated killing is increased by zoledronate. International Journal of Oncology, 2016, 48, 1794-1804.	1.4	13
100	Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease. Current Opinion in Immunology, 2016, 40, 51-61.	2.4	12
101	Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death and Differentiation, 2016, 23, 938-951.	5.0	104
102	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. Molecular Diagnosis and Therapy, 2016, 20, 175-181.	1.6	30
103	Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death and Differentiation, 2016, 23, 962-978.	5.0	506
104	Combining antibodyâ€“drug conjugates and immune-mediated cancer therapy: What to expect?. Biochemical Pharmacology, 2016, 102, 1-6.	2.0	119
105	Current progress in immunotherapy for pancreatic cancer. Cancer Letters, 2016, 381, 244-251.	3.2	149
106	Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochemical and Biophysical Research Communications, 2016, 469, 138-143.	1.0	23
107	Small Molecule Inhibitors of Ca²⁺-S100B Reveal Two Protein Conformations. Journal of Medicinal Chemistry, 2016, 59, 592-608.	2.9	13
108	Combination cancer immunotherapies tailored to the tumour microenvironment. Nature Reviews Clinical Oncology, 2016, 13, 143-158.	12.5	753
109	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. Nature Reviews Clinical Oncology, 2017, 14, 115-128.	12.5	95
110	Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E761-E770.	3.3	295
111	Immune Checkpoint Inhibitors in Lung Cancer â€“ An Unheralded Opportunity?. Clinical Oncology, 2017, 29, 207-217.	0.6	6
112	Comparison of patient-derived high and low phosphatidylserine-exposing colorectal carcinoma cells in their interaction with anti-cancer peptides. Journal of Peptide Science, 2017, 23, 56-67.	0.8	4
113	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44

#	Article	IF	Citations
114	Multifaceted Immunomodulatory Nanoliposomes: Reshaping Tumors into Vaccines for Enhanced Cancer Immunotherapy. Advanced Functional Materials, 2017, 27, 1605398.	7.8	64
115	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
116	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clinical Cancer Research, 2017, 23, 4462-4472.	3.2	85
117	Macrophage regulation of B cell proliferation. Cellular Immunology, 2017, 314, 54-62.	1.4	12
118	Armed Oncolytic Adenovirusâ€"Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Research, 2017, 77, 2040-2051.	0.4	170
119	Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation. Nucleus (India), 2017, 60, 93-109.	0.9	4
120	The Principles of Engineering Immune Cells to Treat Cancer. Cell, 2017, 168, 724-740.	13.5	844
121	Resistance to immunotherapy: clouds in a bright sky. Investigational New Drugs, 2017, 35, 649-654.	1.2	8
122	Combined antiangiogenic and antiâ€"PD-L1 therapy stimulates tumor immunity through HEV formation. Science Translational Medicine, 2017, 9, .	5.8	541
123	Global survey of the immunomodulatory potential of common drugs. Nature Chemical Biology, 2017, 13, 681-690.	3.9	53
124	Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches. BioDrugs, 2017, 31, 143-149.	2.2	11
125	In vivo imaging reveals a tumor-associated macrophageâ€"mediated resistance pathway in antiâ€"PD-1 therapy. Science Translational Medicine, 2017, 9, .	5.8	466
126	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. International Journal of Cancer, 2017, 141, 572-582.	2.3	53
127	Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression. Immunological Investigations, 2017, 46, 134-148.	1.0	36
128	Selfâ€Assembled Nanoâ€Immunostimulant for Synergistic Immune Activation. ChemBioChem, 2017, 18, 1721-1729.	1.3	15
129	Immune checkpoints on innate lymphoid cells. Journal of Experimental Medicine, 2017, 214, 1561-1563.	4.2	18
130	Developments in therapy with monoclonal antibodies and related proteins. Clinical Medicine, 2017, 17, 220-232.	0.8	137
131	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. Journal of Biomedical Science, 2017, 24, 35.	2.6	88

#	Article	IF	Citations
132	Highlights lecture EANM 2016: â€œEmbracing molecular imaging and multi-modal imaging: a smart move for nuclear medicine towards personalized medicineâ€• European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1559-1574.	3.3	19
133	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. Molecular and Cellular Proteomics, 2017, 16, 1705-1717.	2.5	56
134	Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology. SLAS Discovery, 2017, 22, 1182-1192.	1.4	21
135	STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. Journal of Dental Research, 2017, 96, 1027-1034.	2.5	147
136	Development of novel avenues to overcome challenges facing CAR T cells. Translational Research, 2017, 187, 22-31.	2.2	4
137	Cytomegalovirus vector expressing RAEâ€1Î³ induces enhanced antiâ€tumor capacity of murine CD8⁺ T cells. European Journal of Immunology, 2017, 47, 1354-1367.	1.6	18
138	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. Journal of Medicinal Chemistry, 2017, 60, 5857-5867.	2.9	242
139	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. OncoImmunology, 2017, 6, e1313371.	2.1	11
140	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. Therapeutic Advances in Medical Oncology, 2017, 9, 431-439.	1.4	73
141	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	2.1	332
142	Targeting ligandâ€“receptor interactions for development of cancer therapeutics. Current Opinion in Chemical Biology, 2017, 38, 62-69.	2.8	32
143	Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nature Reviews Cancer, 2017, 17, 286-301.	12.8	742
144	Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. Journal of Clinical Pathology, 2017, 70, 860-867.	1.0	47
145	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clinical Cancer Research, 2017, 23, 4429-4440.	3.2	142
146	The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production. Journal of Immunology, 2017, 198, 4129-4139.	0.4	62
147	Antibodies and associates: Partners in targeted drug delivery. , 2017, 177, 129-145.		52
148	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. Journal of Experimental Medicine, 2017, 214, 895-904.	4.2	614
149	The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics, 2017, 17, 459-470.	1.5	11

#	Article	IF	Citations
150	Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy. Annual Review of Cancer Biology, 2017, 1, 447-466.	2.3	28
151	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. European Journal of Cancer, 2017, 76, 152-166.	1.3	82
152	New concepts of personalized therapy in salivary gland carcinomas. Oral Oncology, 2017, 68, 103-113.	0.8	36
153	A covalent antagonist for the human adenosine A2A receptor. Purinergic Signalling, 2017, 13, 191-201.	1.1	22
154	Autoimmune Cardiotoxicity of Cancer Immunotherapy. Trends in Immunology, 2017, 38, 77-78.	2.9	32
155	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. Blood, 2017, 129, 275-279.	0.6	85
156	A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. Annals of Oncology, 2017, 28, 798-803.	0.6	43
157	Emerging treatments for classical myeloproliferative neoplasms. Blood, 2017, 129, 693-703.	0.6	84
158	Role of Fcâ€“FcÎ³R interactions in the antitumor activity of therapeutic antibodies. Immunology and Cell Biology, 2017, 95, 340-346.	1.0	35
159	Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncology, The, 2017, 18, e653-e706.	5.1	153
160	Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade. Cancer Immunology Research, 2017, 5, 950-956.	1.6	125
161	Small-Molecule Targets in Immuno-Oncology. Cell Chemical Biology, 2017, 24, 1148-1160.	2.5	44
162	Nuclear and Fluorescent Labeled PD-1-Liposome-DOX-⁶⁴Cu/IRDye800CW Allows Improved Breast Tumor Targeted Imaging and Therapy. Molecular Pharmaceutics, 2017, 14, 3978-3986.	2.3	66
163	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open, 2017, 2, e000208.	2.0	47
164	Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 2017, 280, 126-148.	2.8	325
165	Synthetic RNA-Based Immunomodulatory Gene Circuits for Cancer Immunotherapy. Cell, 2017, 171, 1138-1150.e15.	13.5	113
166	Cutting Edge: Antiâ€“TIM-3 Treatment Exacerbates Pulmonary Inflammation and Fibrosis in Mice. Journal of Immunology, 2017, 199, 3733-3737.	0.4	21
167	mTOR co-targeting strategies for head and neck cancer therapy. Cancer and Metastasis Reviews, 2017, 36, 491-502.	2.7	46

#	Article	IF	Citations
168	Adoptive cell therapy in multiple Myeloma. Expert Opinion on Biological Therapy, 2017, 17, 1511-1522.	1.4	19
169	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology, 2017, 6, e1371896.	2.1	36
170	Tumour radiosensitivity is associated with immune activation in solid tumours. European Journal of Cancer, 2017, 84, 304-314.	1.3	44
171	Nanomaterials for cancer immunotherapy. Biomaterials, 2017, 148, 16-30.	5.7	226
172	Bioactive Macrocyclic Inhibitors of the PDâ€1/PDâ€L1 Immune Checkpoint. Angewandte Chemie, 2017, 129, 13920-13923.	1.6	13
173	A Dynamic Metabolic Flux Analysis of Myeloid-Derived Suppressor Cells Confirms Immunosuppression-Related Metabolic Plasticity. Scientific Reports, 2017, 7, 9850.	1.6	28
174	Expression of PD-L1 in Hormone-naÃ¯ve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide. Clinical Cancer Research, 2017, 23, 6812-6822.	3.2	77
175	SOCS1: Regulator of T Cells in Autoimmunity and Cancer. Current Topics in Microbiology and Immunology, 2017, 410, 159-189.	0.7	18
176	Discovery and application of immune biomarkers for hematological malignancies. Expert Review of Molecular Diagnostics, 2017, 17, 983-1000.	1.5	6
178	Bioactive Macrocyclic Inhibitors of the PDâ€1/PDâ€L1 Immune Checkpoint. Angewandte Chemie - International Edition, 2017, 56, 13732-13735.	7.2	131
179	Atezolizumab for the treatment of non-small cell lung cancer. Expert Review of Clinical Pharmacology, 2017, 10, 935-945.	1.3	34
180	Nivolumab for the treatment of bladder cancer. Expert Opinion on Biological Therapy, 2017, 17, 1309-1315.	1.4	13
181	Shifting the balance of power? The combination of oncolytic virotherapy and immune checkpoint blockade for glioblastoma treatment. Neuro-Oncology, 2017, 19, 463-465.	0.6	2
182	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. Structure, 2017, 25, 1163-1174.	1.6	253
183	Immunotherapyâ€¦ a pursuit race to tomorrow's medicines. Future Medicinal Chemistry, 2017, 9, 1297-1299.	1.1	3
184	CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature, 2017, 549, 101-105.	13.7	624
185	Structureâ€“Activity Relationships and Biological Characterization of a Novel, Potent, and Serum Stable C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonist. Journal of Medicinal Chemistry, 2017, 60, 9641-9652.	2.9	21
186	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. Journal of Immunology, 2017, 199, 4110-4123.	0.4	37

#	Article	IF	Citations
187	Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 9617-9629.	2.9	118
188	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. Current Oncology Reports, 2017, 19, 49.	1.8	23
189	Molecular Dissection of CD8 + T-Cell Dysfunction. Trends in Immunology, 2017, 38, 567-576.	2.9	51
190	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. Cancer Journal (Sudbury, Mass), 2017, 23, 10-22.	1.0	45
191	CEACAM1 as a Multi-Purpose Target for Cancer Immunotherapy. OncoImmunology, 2017, 6, 00-00.	2.1	79
192	Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Annals of Oncology, 2017, 28, 1923-1933.	0.6	153
193	Biomarkers of response to PD-1/PD-L1 inhibition. Critical Reviews in Oncology/Hematology, 2017, 116, 116-124.	2.0	249
194	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine and Growth Factor Reviews, 2017, 36, 5-15.	3.2	48
195	Immune checkpoints in chronic obstructive pulmonary disease. European Respiratory Review, 2017, 26, 170045.	3.0	27
196	Immunosenescence: limitations of natural killer cell-based cancer immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 233-245.	2.0	33
197	Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. European Urology, 2017, 71, 776-787.	0.9	81
198	Local delivery of checkpoints antibodies. Human Vaccines and Immunotherapeutics, 2017, 13, 245-248.	1.4	16
199	Ru(III) anticancer agents with aromatic and non-aromatic dithiocarbamates asligands: Loading into nanocarriers and preliminary biological studies. Journal of Inorganic Biochemistry, 2017, 166, 76.	1.5	4
200	Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials, 2017, 112, 153-163.	5.7	215
201	Oncolytic Viruses in Cancer Treatment. JAMA Oncology, 2017, 3, 841.	3.4	426
202	Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer. Seminars in Cell and Developmental Biology, 2017, 64, 90-97.	2.3	39
203	Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. Journal of Neuropathology and Experimental Neurology, 2017, 76, 779-788.	0.9	57
204	Updated Landscape of the Tumor Microenvironment and Targeting Strategies in an Era of Precision Medicine. , 2017, , .		0

#	Article	IF	Citations
205	Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. Frontiers in Pharmacology, 2017, 8, 295.	1.6	74
206	Strategies for Bispecific Single Chain Antibody in Cancer Immunotherapy. Journal of Cancer, 2017, 8, 3689-3696.	1.2	9
207	Immune Checkpoints as a Target for Colorectal Cancer Treatment. International Journal of Molecular Sciences, 2017, 18, 1324.	1.8	112
208	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology, 2017, 8, 561.	1.6	1,276
209	Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Frontiers in Cell and Developmental Biology, 2017, 5, 101.	1.8	65
210	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. International Journal of Molecular Sciences, 2017, 18, 1660.	1.8	33
211	Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. Frontiers in Immunology, 2017, 8, 71.	2.2	84
212	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	2.2	61
213	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. Frontiers in Immunology, 2017, 8, 1804.	2.2	54
214	The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Frontiers in Oncology, 2017, 7, 24.	1.3	187
215	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 67.	1.3	28
216	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. PLoS ONE, 2017, 12, e0179201.	1.1	28
217	Cytokine Therapy in the Tumor Microenvironment. , 2017, , 239-256.		0
218	Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell and Bioscience, 2017, 7, 50.	2.1	346
219	Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 2017, 5, 32.	2.8	33
220	Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy. , 2017, 5, 64.		19
221	Combining vasculature disrupting agent and toll-like receptor 7/8 agonist for cancer therapy. Oncotarget, 2017, 8, 5371-5381.	0.8	28
222	Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer. Oncotarget, 2017, 8, 62868-62879.	0.8	12

#	Article	IF	Citations
223	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget, 2017, 8, 72167-72181.	0.8	221
224	Betulinic acid increases radiosensitization of oral squamous cell carcinoma through inducing Sp1 sumoylation and PTEN expression. Oncology Reports, 2017, 38, 2360-2368.	1.2	15
225	Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. Oncotarget, 2017, 8, 19310-19322.	0.8	81
226	miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression. Oncotarget, 2017, 8, 62143-62153.	0.8	46
227	Antigen-Presenting Cell/Tumour Cell Hybrid Vaccines in Cancer Immunotherapy. , 2017, , .		1
228	Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget, 2017, 8, 67129-67139.	0.8	65
229	Plasmodium parasite as an effective hepatocellular carcinoma antigen glypican-3 delivery vector. Oncotarget, 2017, 8, 24785-24796.	0.8	24
230	Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy. IOP Conference Series: Materials Science and Engineering, 2018, 301, 012020.	0.3	3
231	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Science Advances, 2018, 4, eaar2766.	4.7	416
232	A patent review of IDO1 inhibitors for cancer. Expert Opinion on Therapeutic Patents, 2018, 28, 317-330.	2.4	80
233	Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. Journal of Cancer Research and Clinical Oncology, 2018, 144, 835-844.	1.2	7
234	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). International Journal of Oncology, 2018, 52, 1041-1056.	1.4	4
235	<scp>HOXC</scp>10 promotes proliferation and invasion and induces immunosuppressive gene expression in glioma. FEBS Journal, 2018, 285, 2278-2291.	2.2	35
236	A Dual Immunotherapy Nanoparticle Improves Tâ€Cell Activation and Cancer Immunotherapy. Advanced Materials, 2018, 30, e1706098.	11.1	130
237	Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nature Communications, 2018, 9, 1538.	5.8	49
238	Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. Biomacromolecules, 2018, 19, 2098-2108.	2.6	69
239	Dysregulated T cells in multiple sclerosis. Clinical and Experimental Neuroimmunology, 2018, 9, 20-29.	0.5	23
240	Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFÎ²) Production in Regulatory T-Cells. Journal of Medicinal Chemistry, 2018, 61, 4135-4154.	2.9	65

#	Article	IF	Citations
241	Targeted therapies in cancer. Surgery, 2018, 36, 122-127.	0.1	9
242	ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance. Journal of Immunology, 2018, 200, 2013-2024.	0.4	17
243	Well-Controlled Cell-Trapping Systems for Investigating Heterogeneous Cell-Cell Interactions. Advanced Healthcare Materials, 2018, 7, 1701208.	3.9	1
245	Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. Journal of the National Cancer Institute, 2018, 110, 448-459.	3.0	112
246	Retinoic Acid Receptor-Related Orphan Receptor Î³t (RORÎ³t) Agonists as Potential Small Molecule Therapeutics for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2018, 61, 5794-5804.	2.9	37
247	A new approach to assess drug sensitivity in cells for novel drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 339-346.	2.5	6
249	PD-1/PD-L1 Axis in Lung Cancer. Cancer Journal (Sudbury, Mass), 2018, 24, 15-19.	1.0	61
250	The dawn of vaccines for cancer prevention. Nature Reviews Immunology, 2018, 18, 183-194.	10.6	178
251	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. Oncologist, 2018, 23, 410-421.	1.9	23
252	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
253	Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer, 2018, 118, 9-16.	2.9	944
254	High macrophage PD-L1 expression not responsible for T cell suppression. Cellular Immunology, 2018, 324, 50-58.	1.4	5
255	Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. Cardiovascular Research, 2018, 114, 368-377.	1.8	64
256	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
257	Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients. Clinical Cancer Research, 2018, 24, 4529-4538.	3.2	82
258	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology and Oncology, 2018, 11, 31.	6.9	256
259	Chiral resolution, absolute configuration determination, and stereo-activity relationship study of IDO1 inhibitor NLG919. Tetrahedron, 2018, 74, 3045-3051.	1.0	4
260	Noninvasive PET Imaging of T cells. Trends in Cancer, 2018, 4, 359-373.	3.8	88

#	Article	IF	Citations
261	Kinase inhibitors: the road ahead. Nature Reviews Drug Discovery, 2018, 17, 353-377.	21.5	679
262	The role of trophoblastic epigenetic reprogrammation in benign tumor cells on malignant progression: A molecular hypothesis. Medical Hypotheses, 2018, 113, 68-71.	0.8	0
263	Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. Expert Opinion on Therapeutic Targets, 2018, 22, 453-461.	1.5	15
264	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors. OncoImmunology, 2018, 7, e1450711.	2.1	3
265	Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein. Molecular Cancer Therapeutics, 2018, 17, 1024-1038.	1.9	31
266	Skeletal muscle cells actively shape (auto)immune responses. Autoimmunity Reviews, 2018, 17, 518-529.	2.5	74
267	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. Journal of Cellular Physiology, 2018, 233, 2032-2057.	2.0	116
268	Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Molecular and Cellular Biochemistry, 2018, 437, 13-36.	1.4	29
269	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Nonâ€“Small-Cell Lung Cancer: Where Do We Stand?. Clinical Lung Cancer, 2018, 19, 1-11.	1.1	48
270	Immune checkpoint inhibitor-related myocarditis. Japanese Journal of Clinical Oncology, 2018, 48, 7-12.	0.6	57
271	Combination therapy strategies for improving PDâ€1 blockade efficacy: a new era in cancer immunotherapy. Journal of Internal Medicine, 2018, 283, 110-120.	2.7	162
272	Immunotherapy and Lung Cancer. , 2018, , 501-511.e3.		2
273	Neurological Complications of Immune-Based Therapies. , 2018, , 335-344.		0
274	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discovery, 2018, 8, 216-233.	7.7	503
275	Cyclin Dâ€“CDK4 kinase destabilizes PD-L1 via cullin 3â€“SPOP to control cancer immune surveillance. Nature, 2018, 553, 91-95.	13.7	660
276	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. Cancer Immunology Research, 2018, 6, 59-68.	1.6	26
277	Tumor immunotherapy: New aspects of natural killer cells. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 173-196.	0.7	52
278	The role of immune checkpoint inhibitors in non-small cell lung cancer. Shanghai Chest, 0, 2, 35-35.	0.3	0

#	Article	IF	Citations
279	Immunotherapy in pancreatic adenocarcinomaâ€"overcoming barriers to response. Journal of Gastrointestinal Oncology, 2018, 9, 143-159.	0.6	42
280	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S433-S450.	0.6	15
281	Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?. Journal of Thoracic Disease, 2018, 10, S1427-S1437.	0.6	11
282	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. Journal of Thoracic Disease, 2018, 10, 6378-6382.	0.6	13
283	Cytokine-induced killer cell/dendritic cellâ€"cytokine-induced killer cell immunotherapy for the postoperative treatment of gastric cancer. Medicine (United States), 2018, 97, e12230.	0.4	14
284	Possibilities for the Therapy of Melanoma: Current Knowledge and Future Directions. , 2018, , .		1
285	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to singleâ€agent checkpoint blockade. Clinical and Translational Medicine, 2018, 7, 32.	1.7	29
286	TSC2-deficient tumors have evidence of T cell exhaustion and respond to antiâ€"PD-1/antiâ€"CTLA-4 immunotherapy. JCI Insight, 2018, 3, .	2.3	49
287	Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. International Journal of Molecular Sciences, 2018, 19, 3480.	1.8	153
288	Combination of PD-1 blockade and RetroNectin^{Â®}-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. Immunotherapy, 2018, 10, 1315-1323.	1.0	6
289	Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells. PLoS ONE, 2018, 13, e0206818.	1.1	16
290	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Frontiers in Microbiology, 2018, 9, 3158.	1.5	66
291	Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Research, 2018, 78, 6717-6725.	0.4	155
292	Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers, 2018, 10, 469.	1.7	36
293	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium. Frontiers in Pharmacology, 2018, 9, 1300.	1.6	602
294	Taste receptor T1R1/T1R3 promotes the tumoricidal activity of hepatic CD49a+CD49bâ^'natural killer cells. European Journal of Immunology, 2018, 48, 2031-2041.	1.6	5
295	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 2018, 8, 351.	1.3	71
296	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer, 2018, 18, 910.	1.1	9

#	Article	IF	Citations
297	Recent Progresses in Phototherapyâ€Synergized Cancer Immunotherapy. Advanced Functional Materials, 2018, 28, 1804688.	7.8	234
298	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. Trends in Biochemical Sciences, 2018, 43, 1014-1032.	3.7	151
299	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Frontiers in Pharmacology, 2018, 9, 1050.	1.6	48
300	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. Cancer Treatment Reviews, 2018, 70, 232-244.	3.4	36
301	Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma. Scientific Reports, 2018, 8, 15732.	1.6	23
302	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Medicine, 2018, 10, 79.	3.6	36
303	MUC1 Mucin: A Putative Regulatory (Checkpoint) Molecule of T Cells. Frontiers in Immunology, 2018, 9, 2391.	2.2	25
305	Durvalumab in NSCLC: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591880415.	1.4	22
306	Predictive biomarkers for tumor immune checkpoint blockade. Cancer Management and Research, 2018, Volume 10, 4501-4507.	0.9	18
307	Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells. PLoS ONE, 2018, 13, e0206182.	1.1	6
308	Injectable Hydrogels as Unique Platforms for Local Chemotherapeuticsâ€Based Combination Antitumor Therapy. Macromolecular Bioscience, 2018, 18, e1800240.	2.1	65
309	Discovery of 4-Azaindole Inhibitors of TGFÎ²RI as Immuno-oncology Agents. ACS Medicinal Chemistry Letters, 2018, 9, 1117-1122.	1.3	18
310	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. Advances in Experimental Medicine and Biology, 2018, 1092, 113-138.	0.8	19
311	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opinion on Emerging Drugs, 2018, 23, 283-299.	1.0	44
312	Immunoengineering through cancer vaccines â€“ A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release, 2018, 289, 125-145.	4.8	31
313	Photodynamic Therapy Based on Nanoscale Metalâ€“Organic Frameworks: From Material Design to Cancer Nanotherapeutics. Chemistry - an Asian Journal, 2018, 13, 3122-3149.	1.7	71
314	3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab on A Chip, 2018, 18, 3129-3143.	3.1	185
315	Uncovering the underlying physical mechanism for cancer-immunity of MHC class I diversity. Biochemical and Biophysical Research Communications, 2018, 504, 532-537.	1.0	3

#	Article	IF	Citations
316	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121
317	Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy. Molecular Cancer Therapeutics, 2018, 17, 2530-2542.	1.9	59
318	The Molecular Imaging of Natural Killer Cells. Molecular Imaging, 2018, 17, 153601211879481.	0.7	16
319	Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Frontiers in Immunology, 2018, 9, 2103.	2.2	56
320	Immune Checkpoint Blockade and Immune Monitoring. , 0, , .		1
321	A case of drug-induced Gravesâ€™ Orbitopathy after combination therapy with Tremelimumab and Durvalumab. Journal of Endocrinological Investigation, 2018, 41, 877-878.	1.8	11
322	STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nature Communications, 2018, 9, 1908.	5.8	282
323	Cancer Cell Membrane-Coated Adjuvant Nanoparticles with Mannose Modification for Effective Anticancer Vaccination. ACS Nano, 2018, 12, 5121-5129.	7.3	505
324	Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade. Advanced Materials, 2018, 30, e1801527.	11.1	233
325	Antibody-Drug Conjugates: Targeting the Tumor Microenvironment. Cancer Drug Discovery and Development, 2018, , 299-319.	0.2	4
326	A Convergence-Based Framework for Cancer Drug Resistance. Cancer Cell, 2018, 33, 801-815.	7.7	181
327	Combination of fucoidan-based magnetic nanoparticles and immunomodulators enhances tumour-localized immunotherapy. Nature Nanotechnology, 2018, 13, 746-754.	15.6	218
328	Thinking Cancer. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2018, 37, 117-125.	0.8	3
329	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. Current Urology Reports, 2018, 19, 68.	1.0	12
330	Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 51-66.	3.3	241
331	Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor. OncoImmunology, 2018, 7, e1484982.	2.1	33
332	Checkpoint inhibitors as treatment for malignant gliomas: â€œA long way to the topâ€• Cancer Treatment Reviews, 2018, 69, 121-131.	3.4	46
333	Nivolumab and its use in the second-line treatment of metastatic urothelial cancer. Future Oncology, 2018, 14, 2683-2690.	1.1	1

#	Article	IF	Citations
334	Tumor microenvironment participates in metastasis of pancreatic cancer. Molecular Cancer, 2018, 17, 108.	7.9	361
335	Extracellular vesicles: important collaborators in cancer progression. Essays in Biochemistry, 2018, 62, 149-163.	2.1	55
336	Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. Journal of Controlled Release, 2018, 286, 369-380.	4.8	70
337	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 925-930.	0.7	5
338	Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T. International Journal of Molecular Sciences, 2018, 19, 340.	1.8	157
339	CD4+ T cell help in cancer immunology and immunotherapy. Nature Reviews Immunology, 2018, 18, 635-647.	10.6	1,030
340	Immuno-Oncology: Emerging Targets and Combination Therapies. Frontiers in Oncology, 2018, 8, 315.	1.3	244
341	Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. Frontiers in Immunology, 2018, 9, 414.	2.2	272
342	Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers, 2018, 10, 6.	1.7	158
343	Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. Journal of Controlled Release, 2018, 285, 23-34.	4.8	44
344	Polymer nanoparticles as adjuvants in cancer immunotherapy. Nano Research, 2018, 11, 5769-5786.	5.8	66
345	Activation of NKT Cells in an Anti-PD-1â€“Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells. Cancer Research, 2018, 78, 5315-5326.	0.4	44
346	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacologica Sinica, 2018, 39, 1693-1698.	2.8	39
347	Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. MAbs, 2018, 10, 1-13.	2.6	31
348	Enhanced Tumor Retention Effect by Click Chemistry for Improved Cancer Immunochemotherapy. ACS Applied Materials & Interfaces, 2018, 10, 17582-17593.	4.0	37
349	VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer, 2018, 18, 511.	1.1	66
351	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. Annual Review of Biomedical Data Science, 2018, 1, 1-27.	2.8	27
352	The HU177 Collagen Epitope Controls Melanoma Cell Migration and Experimental Metastasis by a CDK5/YAP-Dependent Mechanism. American Journal of Pathology, 2018, 188, 2356-2368.	1.9	6

#	Article	IF	Citations
353	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 2018, 24, 1550-1558.	15.2	2,791
354	Diagnostic value of peripheral blood immune profiling in colorectal cancer. Annals of Surgical Treatment and Research, 2018, 94, 312.	0.4	26
355	DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer. Clinical Epigenetics, 2018, 10, 104.	1.8	68
356	Checkpoint blockadeâ€based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. Cancer Medicine, 2018, 7, 4517-4529.	1.3	34
357	Myeloid-derived suppressor cells and their role in gynecological malignancies. Tumor Biology, 2018, 40, 101042831877648.	0.8	22
358	Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. Mammalian Genome, 2018, 29, 694-702.	1.0	29
359	Engineering Platforms for T Cell Modulation. International Review of Cell and Molecular Biology, 2018, 341, 277-362.	1.6	8
360	CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers. International Journal of Endocrinology, 2018, 2018, 1-10.	0.6	20
361	The Role of Toll-Like Receptor in Inflammation and Tumor Immunity. Frontiers in Pharmacology, 2018, 9, 878.	1.6	155
362	Safety of combining radiotherapy with immune-checkpoint inhibition. Nature Reviews Clinical Oncology, 2018, 15, 477-494.	12.5	208
363	Innate Immunity in Inflammation. , 2018, , 179-190.		1
364	Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. OncoImmunology, 2018, 7, e1471442.	2.1	7
365	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLoS ONE, 2018, 13, e0190058.	1.1	37
366	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. Leukemia and Lymphoma, 2019, 60, 376-384.	0.6	31
367	Cancer immunotherapy for metastasis: past, present and future. Briefings in Functional Genomics, 2019, 18, 140-146.	1.3	10
368	DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade. Frontiers in Genetics, 2019, 10, 724.	1.1	12
369	USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1580-1590.	1.6	94
370	PD-L1 Distribution and Perspective for Cancer Immunotherapyâ€"Blockade, Knockdown, or Inhibition. Frontiers in Immunology, 2019, 10, 2022.	2.2	270

#	Article	IF	Citations
371	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. Molecular Therapy, 2019, 27, 1878-1891.	3.7	38
372	DNA sensing by the cGASâ€“STING pathway in health and disease. Nature Reviews Genetics, 2019, 20, 657-674.	7.7	801
373	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opinion on Investigational Drugs, 2019, 28, 695-708.	1.9	38
374	Upregulation of PDâ€1 follows tumour development in the AOM/DSS model of inflammationâ€induced colorectal cancer in mice. Immunology, 2019, 158, 35-46.	2.0	32
375	Systematic Immunotherapy Target Discovery Using Genome-Scale InÂVivo CRISPR Screens in CD8ÂT Cells. Cell, 2019, 178, 1189-1204.e23.	13.5	189
376	The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal Therapy. Journal of Cancer, 2019, 10, 3102-3111.	1.2	27
377	Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Nano Letters, 2019, 19, 4879-4889.	4.5	103
378	Japan oncology market overview: Current and future perspectives. Journal of Generic Medicines, 2019, 15, 104-114.	0.0	1
379	Advances and Challenges of Nanoparticle-Based Macrophage Reprogramming for Cancer Immunotherapy. Biochemistry (Moscow), 2019, 84, 729-745.	0.7	8
380	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e344-e351.	2.0	59
381	pH and Thermal Dual-Sensitive Nanoparticle-Mediated Synergistic Antitumor Effect of Immunotherapy and Microwave Thermotherapy. Nano Letters, 2019, 19, 4949-4959.	4.5	42
382	Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy. Bioconjugate Chemistry, 2019, 30, 2115-2126.	1.8	23
383	åšè‚½è•ç‰©åš»„è£…ä½“åœ¨ç™Œç—‡å…ç–«æ²»ç——ä¸šš„åº”ç”¨. Science China Materials, 2019, 62, 1759-1783.	3.5	19
384	Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies. Anticancer Research, 2019, 39, 3917-3921.	0.5	42
385	pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. Genome Medicine, 2019, 11, 67.	3.6	53
386	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. Frontiers in Oncology, 2019, 9, 1066.	1.3	43
387	Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics. Human Pathology, 2019, 94, 58-63.	1.1	6
388	Surface-Layer Protein-Enhanced Immunotherapy Based on Cell Membrane-Coated Nanoparticles for the Effective Inhibition of Tumor Growth and Metastasis. ACS Applied Materials & Interfaces, 2019, 11, 9850-9859.	4.0	73

#	Article	IF	Citations
389	GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity. Nature Communications, 2019, 10, 4804.	5.8	15
390	Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy. International Journal of Pharmaceutics, 2019, 570, 118636.	2.6	24
391	Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity, 2019, 51, 548-560.e4.	6.6	88
392	The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591987036.	1.4	45
393	Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression. Cancer Immunology, Immunotherapy, 2019, 68, 1573-1583.	2.0	15
394	A coreâ€“shell structure QRu-PLGA-RES-DS NP nanocomposite with photothermal response-induced M2 macrophage polarization for rheumatoid arthritis therapy. Nanoscale, 2019, 11, 18209-18223.	2.8	48
395	Inorganic Nanozyme with Combined Self-Oxygenation/Degradable Capabilities for Sensitized Cancer Immunochemotherapy. Nano-Micro Letters, 2019, 11, 74.	14.4	66
396	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. International Journal of Molecular Sciences, 2019, 20, 4654.	1.8	29
397	Radiation Therapy and Immune Modulation. Hematology/Oncology Clinics of North America, 2019, 33, 233-248.	0.9	6
398	Mast cells as protectors of health. Journal of Allergy and Clinical Immunology, 2019, 144, S4-S18.	1.5	88
399	The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Molecular Cancer, 2019, 18, 17.	7.9	239
400	The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. Cancers, 2019, 11, 140.	1.7	18
401	Cold Tumors: A Therapeutic Challenge for Immunotherapy. Frontiers in Immunology, 2019, 10, 168.	2.2	733
402	Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics. Histopathology, 2019, 75, 4-19.	1.6	8
403	Combining immunotherapies to treat non-small cell lung cancer. Expert Review of Respiratory Medicine, 2019, 13, 621-634.	1.0	2
404	Feline <scp>XLF</scp> accumulates at <scp>DNA</scp> damage sites in a Kuâ€dependent manner. FEBS Open Bio, 2019, 9, 1052-1062.	1.0	3
405	Magnetic iron oxide nanoparticles for disease detection and therapy. Materials Today, 2019, 31, 86-99.	8.3	114
406	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. Journal of Oncology, 2019, 2019, 1-14.	0.6	18

#	Article	IF	Citations
407	A tumorâ€targeting nanomedicine carrying the p53 gene crosses the bloodâ€“brain barrier and enhances antiâ€PDâ€1 immunotherapy in mouse models of glioblastoma. International Journal of Cancer, 2019, 145, 2535-2546.	2.3	48
408	A carrier-free multiplexed gene editing system applicable for suspension cells. Biomaterials, 2019, 217, 119298.	5.7	26
409	A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening. Blood, 2019, 134, 171-185.	0.6	47
410	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. Cancer Microenvironment, 2019, 12, 169-179.	3.1	21
411	Perfluorocarbon nanoparticle-mediated platelet inhibition promotes intratumoral infiltration of T cells and boosts immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11972-11977.	3.3	57
412	The Novel Combination of Nitroxoline and PD-1 Blockade, Exerts a Potent Antitumor Effect in a Mouse Model of Prostate Cancer. International Journal of Biological Sciences, 2019, 15, 919-928.	2.6	21
413	A Î²-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator. Carbohydrate Polymers, 2019, 222, 114993.	5.1	26
414	Multifunctional nanocapsules on a seesaw balancing sonodynamic and photodynamic therapies against superficial malignant tumors by effective immune-enhancement. Biomaterials, 2019, 218, 119251.	5.7	43
415	Combining Nanomedicine and Immunotherapy. Accounts of Chemical Research, 2019, 52, 1543-1554.	7.6	310
416	The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 28.	0.4	12
417	Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Letters, 2019, 457, 168-179.	3.2	148
418	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 147-164.	1.8	459
419	Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three Aâ€™s: Abundance, Activation and Antigen-Delivery. Cancers, 2019, 11, 670.	1.7	15
420	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. Frontiers in Immunology, 2019, 10, 999.	2.2	47
421	Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers, 2019, 11, 567.	1.7	17
422	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. Cancers, 2019, 11, 539.	1.7	45
423	Beyond PD-L1 Markers for Lung Cancer Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 1915.	1.8	61
424	Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide. Oral Oncology, 2019, 93, 122-124.	0.8	3

#	Article	IF	Citations
425	Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 220-227.	1.4	10
426	Angiogenesis in Pancreatic Cancer: Pre-Clinical and Clinical Studies. Cancers, 2019, 11, 381.	1.7	66
427	Roles of NKT cells in cancer immunotherapy. Archives of Pharmacal Research, 2019, 42, 543-548.	2.7	72
428	Small Molecules as PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 24, 4911-4920.	0.9	27
429	JQ1, a BETâ€bromodomain inhibitor, inhibits human cancer growth and suppresses PDâ€L1 expression. Cell Biology International, 2019, 43, 642-650.	1.4	24
430	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?. , 2019, 7, 85.		175
431	Immunotherapy in ovarian cancer: fake news or the real deal?. International Journal of Gynecological Cancer, 2019, 29, 201-211.	1.2	37
432	Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 861-870.	2.0	49
433	Emerging Nanoâ€Microapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847.	5.6	136
434	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. Journal of Cancer, 2019, 10, 120-130.	1.2	5
435	Advances in immune checkpoint inhibitors for bone sarcoma therapy. Journal of Bone Oncology, 2019, 15, 100221.	1.0	122
436	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. Cancer Immunology Research, 2019, 7, 630-643.	1.6	217
437	Neuropilins in the Context of Tumor Vasculature. International Journal of Molecular Sciences, 2019, 20, 639.	1.8	58
438	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. Nature Reviews Cardiology, 2019, 16, 325-343.	6.1	65
439	Gene-based Interventions for Cancer Immunotherapy. , 0, , .		0
441	EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma. , 2019, 7, 300.		114
443	4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth. Scientific Reports, 2019, 9, 18455.	1.6	24
444	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research, 2019, 40, 243-250.	0.3	26

#	Article	IF	Citations
445	Gut microbiome and CAR-T therapy. Experimental Hematology and Oncology, 2019, 8, 31.	2.0	33
446	Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor. Frontiers in Oncology, 2019, 9, 1196.	1.3	39
447	Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer Cell, 2019, 36, 582-596.	7.7	201
448	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Nonâ€“Small Cell Lung Cancer. Integrative Cancer Therapies, 2019, 18, 153473541989002.	0.8	33
449	Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients. Medicine (United States), 2019, 98, e15731.	0.4	29
450	Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine, 2019, 8, 2168.	1.0	85
451	Gynecologic Malignancies. , 2019, , 135-155.		0
452	Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy. Theranostics, 2019, 9, 126-151.	4.6	128
453	Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors. OncoImmunology, 2019, 8, e1542245.	2.1	18
454	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 199-224.	3.3	53
455	Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine, 2019, 40, 457-470.	2.7	177
456	PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas. Human Pathology, 2019, 86, 155-162.	1.1	15
457	Identification and characterization of an alternative cancer-derived PD-L1 splice variant. Cancer Immunology, Immunotherapy, 2019, 68, 407-420.	2.0	53
458	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
459	Progress in Tumorâ€Associated Macrophages: From Bench to Bedside. Advanced Biology, 2019, 3, e1800232.	3.0	12
460	Neural regulation of drug resistance in cancer treatment. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 20-28.	3.3	8
461	Cancer Diagnostics and Therapeutics. Bioanalysis, 2019, , 33-66.	0.1	0
462	A new immune-nanoplatform for promoting adaptive antitumor immune response. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 13-25.	1.7	17

#	Article	IF	Citations
463	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 861-867.	2.0	36
464	Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma. Journal of Dental Research, 2019, 98, 268-276.	2.5	27
465	Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. AAPS Journal, 2019, 21, 18.	2.2	8
466	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. European Journal of Medicinal Chemistry, 2019, 161, 378-398.	2.6	66
467	T-cell trafficking plays an essential role in tumor immunity. Laboratory Investigation, 2019, 99, 85-92.	1.7	11
468	Theragnostic potentials of core/shell mesoporous silica nanostructures. Nanotheranostics, 2019, 3, 1-40.	2.7	37
469	Circulating myeloidâ€derived suppressor cells: An independent prognostic factor in patients with breast cancer. Journal of Cellular Physiology, 2019, 234, 3515-3525.	2.0	62
470	Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. Methods in Molecular Biology, 2019, 1904, 83-108.	0.4	47
471	Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health. Pharmacological Reviews, 2019, 71, 1-19.	7.1	47
472	Preparation and optimization of poly (lactic acid) nanoparticles loaded with fisetin to improve anti-cancer therapy. International Journal of Biological Macromolecules, 2019, 125, 700-710.	3.6	70
473	HSP90: Enabler of Cancer Adaptation. Annual Review of Cancer Biology, 2019, 3, 275-297.	2.3	59
474	Immune checkpoint blockade resistance-related B2M hotspot mutations in microsatellite-unstable colorectal carcinoma. Pathology Research and Practice, 2019, 215, 209-214.	1.0	28
475	Hematopoietic Progenitor Kinase-1 Structure in a Domain-Swapped Dimer. Structure, 2019, 27, 125-133.e4.	1.6	26
476	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
477	Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. Journal of Drug Targeting, 2019, 27, 244-256.	2.1	86
478	Genomic and epigenomic perspectives of T-cell exhaustion in cancer. Briefings in Functional Genomics, 2019, 18, 113-118.	1.3	6
480	Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses. Methods in Enzymology, 2020, 636, 185-207.	0.4	9
481	Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Seminars in Cancer Biology, 2020, 64, 1-12.	4.3	93

#	Article	IF	Citations
482	Therapeutic Antibodies and Immunologic Conjugates. , 2020, , 486-499.e8.		2
483	Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. Journal of Nuclear Cardiology, 2020, 27, 1210-1224.	1.4	18
484	Benefit, burden, and impact for a cohort of post-approval cancer combination trials. Clinical Trials, 2020, 17, 18-29.	0.7	5
485	Advances of functional nanomaterials for cancer immunotherapeutic applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1574.	3.3	10
486	One pot preparation of polyurethaneâ€based GSHâ€responsive coreâ€shell nanogels for controlled drug delivery. Journal of Applied Polymer Science, 2020, 137, 48473.	1.3	6
487	Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint. Protein Expression and Purification, 2020, 166, 105520.	0.6	4
488	Management of neoplastic pericardial disease. Herz, 2020, 45, 46-51.	0.4	4
489	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
490	Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma. Biomaterials, 2020, 230, 119599.	5.7	79
491	New Approaches on Cancer Immunotherapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036863.	2.9	17
492	Combination of Bacterialâ€Photothermal Therapy with an Antiâ€PDâ€1 Peptide Depot for Enhanced Immunity against Advanced Cancer. Advanced Functional Materials, 2020, 30, 1906623.	7.8	74
493	Immunotherapy for the Treatment of Breast Cancer: Emerging New Data . Breast Cancer: Targets and Therapy, 2019, Volume 11, 321-328.	1.0	25
495	Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. EBioMedicine, 2020, 51, 102602.	2.7	78
496	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. Journal of Controlled Release, 2020, 318, 270-278.	4.8	30
497	Photodynamic cancer therapy enhances accumulation of nanoparticles in tumor-associated myeloid cells. Journal of Controlled Release, 2020, 320, 19-31.	4.8	26
498	Computational network biology: Data, models, and applications. Physics Reports, 2020, 846, 1-66.	10.3	126
499	Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer. Translational Oncology, 2020, 13, 193-200.	1.7	16
500	Kidney residency of VISTA-positive macrophages accelerates repair from ischemic injury. Kidney International, 2020, 97, 980-994.	2.6	18

#	Article	IF	Citations
501	Multifunctional phototheranostic nanomedicine for cancer imaging and treatment. Materials Today Bio, 2020, 5, 100035.	2.6	167
502	Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PDâ€L1 into extracellular vesicles. FASEB Journal, 2020, 34, 2213-2226.	0.2	55
503	Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment. Cells, 2020, 9, 96.	1.8	60
504	The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix. Pathology Research and Practice, 2020, 216, 152782.	1.0	26
505	New insight in endocrine-related adverse events associated to immune checkpoint blockade. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101370.	2.2	60
506	CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models. Journal of Immunotherapy, 2020, 43, 16-28.	1.2	53
507	Sheddable Prodrug Vesicles Combating Adaptive Immune Resistance for Improved Photodynamic Immunotherapy of Cancer. Nano Letters, 2020, 20, 353-362.	4.5	162
508	Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. Annals of Otology, Rhinology and Laryngology, 2020, 129, 517-522.	0.6	22
509	The biology of cancer. Medicine, 2020, 48, 67-72.	0.2	22
510	Nanoscale metal-organic frameworks for x-ray activated in situ cancer vaccination. Science Advances, 2020, 6, .	4.7	40
511	Mammalian Expression and In Situ Biotinylation of Extracellular Protein Targets for Directed Evolution. ACS Omega, 2020, 5, 25440-25455.	1.6	2
512	BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy. Cell Reports, 2020, 32, 108073.	2.9	30
513	Light-Responsive Coreâ€“Shell Nanoplatform for Bimodal Imaging-Guided Photothermal Therapy-Primed Cancer Immunotherapy. ACS Applied Materials & Interfaces, 2020, 12, 48420-48431.	4.0	35
514	Design of next-generation therapeutic IgG4 with improved manufacturability and bioanalytical characteristics. MAbs, 2020, 12, 1829338.	2.6	4
515	The Resistance Mechanisms of Lung Cancer Immunotherapy. Frontiers in Oncology, 2020, 10, 568059.	1.3	47
517	Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis. IScience, 2020, 23, 101499.	1.9	33
518	Immunotherapies and Combination Strategies for Immuno-Oncology. International Journal of Molecular Sciences, 2020, 21, 5009.	1.8	63
519	PD1 expression on bone marrow Tâ€cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy. EJHaem, 2020, 1, 51-57.	0.4	0

#	Article	IF	Citations
520	Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy. Small, 2020, 16, e2004905.	5.2	16
521	Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?. Journal of Thoracic Disease, 2020, 12, 6070-6089.	0.6	4
522	Emerging Autophagy Functions Shape the Tumor Microenvironment and Play a Role in Cancer Progression - Implications for Cancer Therapy. Frontiers in Oncology, 2020, 10, 606436.	1.3	43
523	Nanomaterial-Based Tumor Photothermal Immunotherapy . International Journal of Nanomedicine, 2020, Volume 15, 9159-9180.	3.3	104
524	RNA sequencing: new technologies and applications in cancer research. Journal of Hematology and Oncology, 2020, 13, 166.	6.9	229
525	Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules, 2020, 25, 5686.	1.7	19
526	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis. International Immunopharmacology, 2020, 87, 106852.	1.7	3
527	Past, Present, and Future of Anticancer Nanomedicine . International Journal of Nanomedicine, 2020, Volume 15, 5719-5743.	3.3	23
528	Recent Progress on Activatable Nanomedicines for Immunometabolic Combinational Cancer Therapy. Small Structures, 2020, 1, 2000026.	6.9	54
529	Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model. Frontiers in Immunology, 2020, 11, 1514.	2.2	23
530	Novel cucurmosinâ€based immunotoxin targeting programmed cell death 1â€ligand 1 with high potency against human tumor in vitro and in vivo. Cancer Science, 2020, 111, 3184-3194.	1.7	10
531	FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Letters, 2020, 490, 174-185.	3.2	169
532	Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opinion on Therapeutic Patents, 2020, 30, 677-694.	2.4	6
533	Charge and Size Dual Switchable Nanocage for Novel Tripleâ€Interlocked Combination Therapy Pattern. Advanced Science, 2020, 7, 2000906.	5.6	20
534	Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma. International Immunopharmacology, 2020, 87, 106802.	1.7	8
535	Vaccination in patients under monoclonal antibody treatment: an updated comprehensive review. Expert Review of Vaccines, 2020, 19, 727-744.	2.0	0
536	Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 5181.	1.8	17
537	KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28239-28250.	3.3	37

#	Article	IF	Citations
538	CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC). Cancer Cell International, 2020, 20, 519.	1.8	21
539	Rewiring Mitochondrial Metabolism for CD8+ T Cell Memory Formation and Effective Cancer Immunotherapy. Frontiers in Immunology, 2020, 11, 1834.	2.2	26
540	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. Biomaterials, 2020, 263, 120380.	5.7	11
541	Inducing Endoplasmic Reticulum Stress to Expose Immunogens: A DNA Tetrahedron Nanoregulator for Enhanced Immunotherapy. Advanced Functional Materials, 2020, 30, 2000532.	7.8	35
542	Implantable Bioresponsive Nanoarray Enhances Postsurgical Immunotherapy by Activating Pyroptosis and Remodeling Tumor Microenvironment. Advanced Functional Materials, 2020, 30, 2005747.	7.8	36
543	Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. Trends in Immunology, 2020, 41, 948-963.	2.9	41
544	A Biomimetic Polymer Magnetic Nanocarrier Polarizing Tumorâ€Associated Macrophages for Potentiating Immunotherapy. Small, 2020, 16, e2003543.	5.2	83
545	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Journal of Medicinal Chemistry, 2020, 63, 11271-11285.	2.9	45
546	Antibodyâ€“Drug Conjugates: The Last Decade. Pharmaceuticals, 2020, 13, 245.	1.7	207
547	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23684-23694.	3.3	32
548	Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells, 2020, 9, 2027.	1.8	88
549	Tetramer Immunization and Selection Followed by CELLISA Screening to Generate Monoclonal Antibodies against the Mouse Cytomegalovirus m12 Immunoevasin. Journal of Immunology, 2020, 205, 1709-1717.	0.4	3
550	Stability enhancement in a mAb and Fab coformulation. Scientific Reports, 2020, 10, 21129.	1.6	7
551	Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy. Frontiers in Chemistry, 2020, 8, 597806.	1.8	55
552	Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. Npj Precision Oncology, 2020, 4, 29.	2.3	11
553	A gene expression-based immune signature for lung adenocarcinoma prognosis. Cancer Immunology, Immunotherapy, 2020, 69, 1881-1890.	2.0	18
554	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	6.5	53
555	CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models. OncoImmunology, 2020, 9, 1747688.	2.1	8

#	Article	IF	Citations
556	Recombinant Costimulatory Fusion Proteins as Functional Immunomodulators Enhance Antitumor Activity in Murine B16F10 Melanoma. Vaccines, 2020, 8, 223.	2.1	2
557	Immune Escape Mediated by Exosomal PDâ€L1 in Cancer. Advanced Biology, 2020, 4, e2000017.	3.0	19
558	Mimetic Heat Shock Protein Mediated Immune Process to Enhance Cancer Immunotherapy. Nano Letters, 2020, 20, 4454-4463.	4.5	58
559	Surface engineering of magnetic nanoparticles for hyperthermia and drug delivery. Medical Devices & Sensors, 2020, 3, e10100.	2.7	5
560	Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo. International Journal of Molecular Sciences, 2020, 21, 3816.	1.8	17
561	Cancer immunotherapy: dawn of the death of cancer?. International Reviews of Immunology, 2020, 39, 205-222.	1.5	5
562	Advances in the discovery and development of selective heme-displacing IDO1 inhibitors. Expert Opinion on Drug Discovery, 2020, 15, 1223-1232.	2.5	8
563	Programmable Delivery of Immune Adjuvant to Tumor-Infiltrating Dendritic Cells for Cancer Immunotherapy. Nano Letters, 2020, 20, 4882-4889.	4.5	50
564	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. Cancer Cell, 2020, 37, 324-339.e8.	7.7	126
565	Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma. Frontiers in Oncology, 2020, 10, 168.	1.3	22
566	Development of oncolytic virotherapy: from genetic modification to combination therapy. Frontiers of Medicine, 2020, 14, 160-184.	1.5	40
567	Implementation of the CYP Index for the Design of Selective Tryptophan-2,3-dioxygenase Inhibitors. ACS Medicinal Chemistry Letters, 2020, 11, 541-549.	1.3	19
568	FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity. Theranostics, 2020, 10, 2859-2871.	4.6	36
569	pH-Dependent Grafting of Cancer Cells with Antigenic Epitopes Promotes Selective Antibody-Mediated Cytotoxicity. Journal of Medicinal Chemistry, 2020, 63, 3713-3722.	2.9	11
570	Melanoma immunotherapy: strategies to overcome pharmacological resistance. Expert Review of Anticancer Therapy, 2020, 20, 289-304.	1.1	13
571	Checkpoint inhibitor blockade and epigenetic reprogrammability in CD8+ T-cell activation and exhaustion. , 2020, 8, 251513552090423.	1.4	2
572	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
573	High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Frontiers in Oncology, 2020, 10, 914.	1.3	45

#	Article	IF	Citations
574	Comprehensive Analysis of PD-1 Gene Expression, Immune Characteristics and Prognostic Significance in 1396 Glioma Patients . Cancer Management and Research, 2020, Volume 12, 4399-4410.	0.9	10
575	Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies. Cells, 2020, 9, 1578.	1.8	8
576	Competition NMR for Detection of Hit/Lead Inhibitors of Proteinâ€“Protein Interactions. Molecules, 2020, 25, 3017.	1.7	11
577	Investigating Cellular Recognition Using CRISPR/Cas9 Genetic Screening. Trends in Cell Biology, 2020, 30, 619-627.	3.6	8
578	Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small cell lung carcinoma. Carcinogenesis, 2020, 41, 1203-1212.	1.3	3
579	Immunotherapy combinations for the treatment of patients with solid tumors. Future Oncology, 2020, 16, 1715-1736.	1.1	6
580	Recent progress in tumor photodynamic immunotherapy. Chinese Chemical Letters, 2020, 31, 1709-1716.	4.8	76
581	Understanding the Complexity of the Tumor Microenvironment in K-ras Mutant Lung Cancer: Finding an Alternative Path to Prevention and Treatment. Frontiers in Oncology, 2019, 9, 1556.	1.3	27
582	Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Biomedicine and Pharmacotherapy, 2020, 125, 109746.	2.5	57
583	Helper Innate Lymphoid Cells in Human Tumors: A Double-Edged Sword?. Frontiers in Immunology, 2019, 10, 3140.	2.2	9
584	Pre-clinical models of small cell lung cancer and the validation of therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 187-204.	1.5	4
585	Unleashing Natural Killer Cells in the Tumor Microenvironmentâ€“The Next Generation of Immunotherapy?. Frontiers in Immunology, 2020, 11, 275.	2.2	101
586	Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer. Pathology Research and Practice, 2020, 216, 152852.	1.0	12
587	The importance of exosomal PDL1 inÂtumour immune evasion. Nature Reviews Immunology, 2020, 20, 209-215.	10.6	360
588	Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells, 2020, 9, 263.	1.8	43
589	TGFÎ±L3-SEB fusion protein as an anticancer against ovarian cancer. European Journal of Pharmacology, 2020, 870, 172919.	1.7	5
590	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer, 2020, 18, 351-360.e3.	0.9	14
591	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. Frontiers in Oncology, 2019, 9, 1486.	1.3	20

#	Article	IF	Citations
592	Neuropilin: Handyman and Power Broker in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1223, 31-67.	0.8	22
593	Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer. Cell, 2020, 181, 442-459.e29.	13.5	741
594	Dissecting the Tumorâ€"Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. Clinical Cancer Research, 2020, 26, 3505-3513.	3.2	18
595	Current updates and future perspectives on the management of renal cell carcinoma. Life Sciences, 2021, 264, 118632.	2.0	48
596	The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure. Bioactive Materials, 2021, 6, 697-711.	8.6	10
597	Identification of prognosis-related genes in the cervical cancer immune microenvironment. Gene, 2021, 766, 145119.	1.0	28
598	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2021, 219, 107694.		79
599	Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet, The, 2021, 397, 1010-1022.	6.3	196
600	Activatable Polymeric Nanoprobe for Nearâ€Infrared Fluorescence and Photoacoustic Imaging of Tâ€...Lymphocytes. Angewandte Chemie - International Edition, 2021, 60, 5921-5927.	7.2	140
601	IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway. Cancer Letters, 2021, 500, 132-146.	3.2	42
602	Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy. Bioorganic and Medicinal Chemistry, 2021, 30, 115951.	1.4	7
603	Activatable Polymeric Nanoprobe for Nearâ€Infrared Fluorescence and Photoacoustic Imaging of Tâ€...Lymphocytes. Angewandte Chemie, 2021, 133, 5986-5992.	1.6	43
604	Baicalin mediated regulation of key signaling pathways in cancer. Pharmacological Research, 2021, 164, 105387.	3.1	69
605	Promising potential of [177Lu]Lu-DOTA-folate to enhance tumor response to immunotherapyâ€"a preclinical study using a syngeneic breast cancer model. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 984-994.	3.3	16
606	Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study. Cancer Immunology, Immunotherapy, 2021, 70, 701-712.	2.0	40
607	Reinvigorating exhausted CD8⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Medicinal Research Reviews, 2021, 41, 156-201.	5.0	56
608	Impact of PD-1 gene polymorphism and its interaction with tea drinking on susceptibility to tuberculosis. Epidemiology and Infection, 2021, 149, e29.	1.0	1
609	HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy. Pharmaceutics, 2021, 13, 179.	2.0	4

#	Article	IF	Citations
610	Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects. Drug Delivery, 2021, 28, 1849-1860.	2.5	7
611	Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients. OncoImmunology, 2021, 10, 1915560.	2.1	17
612	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
613	Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC). Journal of Cancer, 2021, 12, 584-594.	1.2	9
614	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. Cancers, 2021, 13, 134.	1.7	67
615	Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model. International Journal of Biological Sciences, 2021, 17, 3554-3572.	2.6	12
616	The EGFRâ€P38 MAPK axis upâ€regulates PDâ€L1 through miRâ€675â€5p and downâ€regulates HLAâ€ABC via hexokinaseâ€2 in hepatocellular carcinoma cells. Cancer Communications, 2021, 41, 62-78.	3.7	28
617	A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints. Biomaterials Science, 2021, 9, 4159-4168.	2.6	18
618	Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis. Journal of Gastrointestinal Oncology, 2021, 12, 112-120.	0.6	14
619	Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nature Communications, 2021, 12, 1222.	5.8	62
620	Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth. Cancers, 2021, 13, 627.	1.7	16
621	Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Journal of Immunology Research, 2021, 2021, 1-15.	0.9	77
622	Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy. Cells, 2021, 10, 492.	1.8	18
623	Down-regulation of the tumor suppressor miR-34a contributes to head and neck cancer by up-regulating the MET oncogene and modulating tumor immune evasion. Journal of Experimental and Clinical Cancer Research, 2021, 40, 70.	3.5	34
624	Targeting Myeloid-Derived Suppressor Cells in Ovarian Cancer. Cells, 2021, 10, 329.	1.8	21
625	Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. Cancer Cell International, 2021, 21, 137.	1.8	15
626	TTN/OBSCN â€˜Doubleâ€Hitâ€™ predicts favourable prognosis, â€˜immuneâ€hotâ€™ subtype and potentially better immunotherapeutic efficacy in colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 3239-3251.	1.6	34
627	Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2021, 6, 72.	7.1	191

#	Article	IF	Citations
628	Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica, 2021, 106, 1330-1342.	1.7	19
630	Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia, 2021, 23, 281-293.	2.3	18
631	Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. Molecular Therapy - Oncolytics, 2021, 20, 373-386.	2.0	10
632	An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity. Clinical Cancer Research, 2021, 27, 3167-3177.	3.2	16
633	Inspired Epigenetic Modulation Synergy with Adenosine Inhibition Elicits Pyroptosis and Potentiates Cancer Immunotherapy. Advanced Functional Materials, 2021, 31, 2100007.	7.8	39
634	The role of exosomes in tumour immunity under radiotherapy: eliciting abscopal effects?. Biomarker Research, 2021, 9, 22.	2.8	13
635	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
636	Mitochondrial Inhibition: a Treatment Strategy in Cancer?. Current Oncology Reports, 2021, 23, 49.	1.8	11
637	Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Letters, 2021, 500, 1-10.	3.2	220
638	The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events. Neurology, 2021, 96, 733-734.	1.5	6
639	A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy. European Journal of Medicinal Chemistry, 2021, 213, 113163.	2.6	3
640	Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint. Molecular Diversity, 2022, 26, 245-264.	2.1	9
641	Anti-cancer effects of polyphenol-rich sugarcane extract. PLoS ONE, 2021, 16, e0247492.	1.1	21
642	The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Annals of Translational Medicine, 2021, 9, 486-486.	0.7	17
643	Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers. Cells, 2021, 10, 1073.	1.8	6
644	Targeted therapies in cancer. Surgery, 2021, 39, 202-207.	0.1	2
645	An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomaterialia, 2021, 124, 179-190.	4.1	115
646	Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC. Frontiers in Oncology, 2021, 11, 659321.	1.3	11

#	Article	IF	Citations
647	Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics, 2021, 11, 640.	1.3	16
648	Activated Regulatory T-Cells, Dysfunctional and Senescent T-Cells Hinder the Immunity in Pancreatic Cancer. Cancers, 2021, 13, 1776.	1.7	24
649	PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis. Frontiers in Immunology, 2021, 12, 655958.	2.2	8
650	Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. Journal of Medical Case Reports, 2021, 15, 244.	0.4	8
651	Tripleâ€'negative breast cancer: A runâ€'through of features, classification and current therapies (Review). Oncology Letters, 2021, 22, 512.	0.8	52
652	Emerging concepts in PD-1 checkpoint biology. Seminars in Immunology, 2021, 52, 101480.	2.7	84
653	Engineering a sustained release vaccine with a pathogen-mimicking manner for robust and durable immune responses. Journal of Controlled Release, 2021, 333, 162-175.	4.8	13
654	Effectiveness and safety of combined therapy versus monotherapy based on immune checkpoint inhibitors and/or targeted drugs as salvage treatment for advanced urothelial carcinoma: a systematic review and meta-analysis. Translational Cancer Research, 2021, 10, 2091-2107.	0.4	0
655	Anticancer Efficacy of Nonthermal Plasma Therapy Combined with PD-L1 Antibody Conjugated Gold Nanoparticles on Oral Squamous Cell Carcinoma. Applied Sciences (Switzerland), 2021, 11, 4559.	1.3	4
656	Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review. Viruses, 2021, 13, 822.	1.5	3
657	Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. Journal of Medicinal Chemistry, 2021, 64, 7646-7666.	2.9	29
658	Intratumoral Foxp3+RORÎ³t+ T cell infiltration determines poor prognosis and immunoevasive contexture in gastric cancer patients. Cancer Immunology, Immunotherapy, 2022, 71, 1-11.	2.0	9
659	Clinical Perspectives to Overcome Acquired Resistance to Antiâ€"Programmed Death-1 and Antiâ€"Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer. Molecules and Cells, 2021, 44, 363-373.	1.0	13
660	A brand new era of cancer immunotherapy: breakthroughs and challenges. Chinese Medical Journal, 2021, 134, 1267-1275.	0.9	15
661	The Value of Immune-Related Genes Signature in Osteosarcoma Based on Weighted Gene Co-expression Network Analysis. Journal of Immunology Research, 2021, 2021, 1-17.	0.9	26
662	Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. Critical Reviews in Oncology/Hematology, 2021, 161, 103304.	2.0	3
663	PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy. Nature Communications, 2021, 12, 2935.	5.8	84
664	From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer. Advanced Materials, 2021, 33, e2008094.	11.1	60

#	Article	IF	Citations
665	In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy. Chinese Chemical Letters, 2021, 32, 1770-1774.	4.8	41
666	Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 4843.	1.8	8
667	Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma. Frontiers in Genetics, 2021, 12, 669694.	1.1	34
668	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230
669	A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Frontiers in Immunology, 2021, 12, 654463.	2.2	16
670	Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. Cancer Treatment Reviews, 2021, 97, 102172.	3.4	27
671	Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy. Cancer Treatment Reviews, 2021, 97, 102192.	3.4	15
672	Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations. Blood, 2021, 138, 1194-1197.	0.6	5
673	Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFÎºB axis. , 2021, 9, e002508.		22
674	Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment. Biochemical Pharmacology, 2021, 188, 114522.	2.0	13
675	Plasmodium infection inhibits triple negative 4T1 breast cancer potentially through induction of CD8+ T cell-mediated antitumor responses in mice. Biomedicine and Pharmacotherapy, 2021, 138, 111406.	2.5	10
676	Development and validation of an individualized immune prognostic model in stage Iâ€“III lung squamous cell carcinoma. Scientific Reports, 2021, 11, 12727.	1.6	12
677	Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. International Journal of Molecular Sciences, 2021, 22, 6290.	1.8	4
678	Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives. Seminars in Liver Disease, 2021, 41, 263-276.	1.8	14
679	In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorganic Chemistry, 2021, 111, 104833.	2.0	37
680	Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model. Molecules, 2021, 26, 3744.	1.7	8
681	Traceable metallic antigen release for enhanced cancer immunotherapy. Journal of Nanoparticle Research, 2021, 23, 130.	0.8	2
682	Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. Journal of Cellular and Molecular Medicine, 2021, 25, 6874-6886.	1.6	29

#	Article	IF	Citations
683	Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor ResponsesIn Vivo. Molecular Cancer Therapeutics, 2021, 20, 1941-1955.	1.9	41
684	Phenolic molecules constructed nanomedicine for innovative cancer treatment. Coordination Chemistry Reviews, 2021, 439, 213912.	9.5	15
685	Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy. Cancer Letters, 2021, 511, 68-76.	3.2	33
686	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Proteinâ€"Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 11614-11636.	2.9	42
687	Ubiquitin ligases in cancer: Functions and clinical potentials. Cell Chemical Biology, 2021, 28, 918-933.	2.5	36
688	Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Frontiers in Pharmacology, 2021, 12, 714483.	1.6	9
689	A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity. Life Sciences, 2021, 277, 119438.	2.0	9
690	Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines, 2021, 9, 724.	2.1	27
691	Overcoming Chemoimmunotherapyâ€Induced Immunosuppression by Assemblable and Depot Forming Immune Modulating Nanosuspension. Advanced Science, 2021, 8, e2102043.	5.6	23
692	Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. Cancers, 2021, 13, 4124.	1.7	17
693	KAT6A Acetylation of SMAD3 Regulates Myeloidâ€Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2100014.	5.6	30
694	Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories. Scientific Reports, 2021, 11, 15713.	1.6	10
695	Magnetic systems for cancer immunotherapy. Acta Pharmaceutica Sinica B, 2021, 11, 2172-2196.	5.7	40
696	PD-1/PD-L1 immune checkpoints: Tumor vs atherosclerotic progression. Clinica Chimica Acta, 2021, 519, 70-75.	0.5	8
697	The best regimens for chemo-naÃ¯ve incurable non-squamous non- small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1â€"49%: a network meta-analysis. Translational Lung Cancer Research, 2021, 10, 3550-3566.	1.3	4
698	Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. BMC Immunology, 2021, 22, 55.	0.9	11
699	Strategies for targeting undruggable targets. Expert Opinion on Drug Discovery, 2022, 17, 55-69.	2.5	34
700	Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead. Journal of Personalized Medicine, 2021, 11, 971.	1.1	5

#	Article	IF	Citations
701	Recent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy. Coordination Chemistry Reviews, 2021, 442, 214009.	9.5	29
703	Role of Different Peptides for Cancer Immunotherapy. International Journal of Peptide Research and Therapeutics, 2021, 27, 2777-2793.	0.9	7
704	Vascular Bursts Act as a Versatile Tumor Vessel Permeation Route for Bloodâ€Borne Particles and Cells. Small, 2021, 17, e2103751.	5.2	11
705	Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models. Pharmaceutics, 2021, 13, 1470.	2.0	13
706	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell, 2021, 184, 4753-4771.e27.	13.5	99
707	Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends in Cancer, 2021, 7, 837-846.	3.8	45
708	Doxorubicin-Near infrared dye conjugate induces immunogenic cell death to enhance cancer immunotherapy. International Journal of Pharmaceutics, 2021, 607, 121027.	2.6	9
709	Bifunctional lipids in tumor vaccines: An outstanding delivery carrier and promising immune stimulator. International Journal of Pharmaceutics, 2021, 608, 121078.	2.6	2
710	Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer. Biomaterials, 2021, 277, 121105.	5.7	15
711	Design, synthesis and antitumor activity evaluation of trifluoromethyl-substituted pyrimidine derivatives. Bioorganic and Medicinal Chemistry Letters, 2021, 51, 128268.	1.0	8
712	Native Mitochondria-Targeting polymeric nanoparticles for mild photothermal therapy rationally potentiated with immune checkpoints blockade to inhibit tumor recurrence and metastasis. Chemical Engineering Journal, 2021, 424, 130171.	6.6	36
713	SH003 overcomes drug resistance and immune checkpoints by inhibiting JAK-STAT3 signaling in MCF7/ADR cells. Phytomedicine Plus, 2021, 1, 100111.	0.9	2
714	Metformin loaded porous particles with bio-microenvironment responsiveness for promoting tumor immunotherapy. Biomaterials Science, 2021, 9, 2082-2089.	2.6	11
715	Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review. Journal of Cancer, 2021, 12, 1318-1333.	1.2	27
716	The phosphatase PAC1 acts as a T cell suppressor and attenuates host antitumor immunity. Nature Immunology, 2020, 21, 287-297.	7.0	73
717	Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy. MAbs, 2019, 11, 681-690.	2.6	30
718	Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response. OncoImmunology, 2021, 10, 1854529.	2.1	19
719	PD-L1 Expression in Extramammary Paget Disease: A Case Series. American Journal of Dermatopathology, 2021, 43, 21-26.	0.3	2

#	Article	IF	Citations
720	Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. Annals of Surgery, 2022, 275, e163-e173.	2.1	17
721	Targeting tumor-resident mast cells for effective anti-melanoma immune responses. JCI Insight, 2019, 4, .	2.3	36
722	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. JCI Insight, 2020, 5, .	2.3	25
723	Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020, 5, .	2.3	177
724	Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight, 2017, 2, .	2.3	34
725	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
726	IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Journal of Clinical Investigation, 2019, 129, 3324-3338.	3.9	209
727	Autophagy- An emerging target for melanoma therapy. F1000Research, 2016, 5, 1888.	0.8	49
728	Master Regulators of Oncogenic KRAS Response in Pancreatic Cancer: An Integrative Network Biology Analysis. PLoS Medicine, 2017, 14, e1002223.	3.9	39
729	Neem leaf glycoprotein prevents post-surgical sarcoma recurrence in Swiss mice by differentially regulating cytotoxic T and myeloid-derived suppressor cells. PLoS ONE, 2017, 12, e0175540.	1.1	8
730	Cancer Immunotherapy and Immunonutrition. MOJ Anatomy & Physiology, 2017, 3, .	0.2	1
731	Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine. Advances in Modern Oncology Research, 2016, 2, 18.	0.1	5
732	Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer. Oncotarget, 2017, 8, 7614-7624.	0.8	46
733	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget, 2017, 8, 22218-22234.	0.8	46
734	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget, 2017, 8, 43555-43570.	0.8	10
735	Inhibition of PI4K IIIÎ± radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model. Oncotarget, 2017, 8, 110392-110405.	0.8	17
736	Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9, 11846-11857.	0.8	2
737	Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models. Oncotarget, 2019, 10, 1399-1406.	0.8	35

#	Article	IF	Citations
738	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 2019, 10, 4532-4545.	0.8	8
739	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget, 2016, 7, 2936-2950.	0.8	40
740	Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis. Oncotarget, 2016, 7, 76523-76533.	0.8	17
741	Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma. Annals of Translational Medicine, 2020, 8, 1478-1478.	0.7	17
742	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 23-23.	0.4	30
743	The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry, 2020, 27, 5654-5674.	1.2	13
744	The Role of Cetuximab in the Induction of Anticancer Immune Response in Colorectal Cancer Treatment. Anticancer Research, 2016, 36, 4421-4426.	0.5	40
745	Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy. Iranian Journal of Basic Medical Sciences, 2020, 23, 1065-1077.	1.0	7
746	Therapeutic status and the prospect of CRISPR/Cas9 gene editing in multiple myeloma. Future Oncology, 2020, 16, 1125-1136.	1.1	3
747	Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World Journal of Gastroenterology, 2016, 22, 4446.	1.4	13
748	Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?. World Journal of Gastroenterology, 2018, 24, 2137-2151.	1.4	99
749	Immunotherapy a New Hope for Cancer Treatment: A Review. Pakistan Journal of Biological Sciences, 2018, 21, 135-150.	0.2	21
750	Cigarette Smoke-Induced Chronic Inflammation Leading to COPD and Lung Cancer: A Multiscale Modeling Study. Journal of Immunobiology, 2017, 02, .	0.3	1
751	Regulatory T cells: balancing protection versus pathology. Swiss Medical Weekly, 2016, 146, w14343.	0.8	19
752	Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. ELife, 2020, 9, .	2.8	40
753	Cancer Immunotherapy Strategies: Basic Principles. Bioanalysis, 2021, , 29-49.	0.1	0
754	A nomogramâ€‘based immunoprofile predicts clinical outcomes for stageÂII and III human colorectal cancer. Molecular and Clinical Oncology, 2021, 15, 257.	0.4	6
755	Recent advancements and future submissions of silica core-shell nanoparticles. International Journal of Pharmaceutics, 2021, 609, 121173.	2.6	17

#	Article	IF	Citations
756	Computational Recognition and Clinical Verification of TGF-Î²-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2021, 11, 757919.	1.3	22
757	Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. Cancers, 2021, 13, 5333.	1.7	29
758	Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer. Frontiers in Oncology, 2021, 11, 714550.	1.3	3
759	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research, 2021, 9, 1465-1475.	1.6	8
760	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. Frontiers in Medicine, 2021, 8, 756870.	1.2	2
761	D-MT prompts the anti-tumor effect of oxaliplatin by inhibiting IDO expression in a mouse model of colon cancer. International Immunopharmacology, 2021, 101, 108203.	1.7	5
762	Omics approaches to individual variation: modeling networks and the virtual patient. Dialogues in Clinical Neuroscience, 2016, 18, 253-265.	1.8	4
763	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0
764	Multiscale Modeling of Inflammation and Inflammatory Diseases. Immunotherapy (Los Angeles, Calif), 2017, 03, .	0.1	0
765	Generation and Gene Expression of CD28â˜’CD8 T Cells in Human. , 2018, , 1-19.		0
766	What about Treatment of Metastatic Bladder Cancer. Chemotherapy, 2018, 07, .	0.0	0
768	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
769	Generation and Gene Expression of CD28â˜’CD8 T Cells in Human. , 2019, , 553-571.		0
770	Identifying the most effective hydatid cyst fluid fraction for anticancer vaccination of 4T1 breast tumor-bearing mice. International Journal of Preventive Medicine, 2019, 10, 143.	0.2	3
771	Insights into breast cancer phenotying through molecular omics approaches and therapy response. , 2019, 2, 527-538.		2
772	Exceptional Responder to Immunotherapy: A Rare Case of Post- HSCT DLBCL Relapse Responding to Nivolumab. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	1
773	Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment. Current Cancer Therapy Reviews, 2019, 15, 110-119.	0.2	0
774	Current Development and Research Trend of Chemotherapeutic Agents for Head and Neck Squamous Cell Carcinoma. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2019, 62, 487-498.	0.0	1

#	Article	IF	Citations
777	Proteomics score: a potential biomarker for the prediction of prognosis in non-small cell lung cancer. Translational Cancer Research, 2019, 8, 1904-1917.	0.4	0
779	The Roles of CD4+ T-Cells in Tumor Immunity. , 2020, , 63-90.		0
783	A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy. Cancer Research, 2021, 81, 6233-6245.	0.4	77
784	Fate and Effects of Cytostatic Pharmaceuticals in the Marine Environment. , 2020, , 295-330.		4
785	Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer. World Journal of Oncology, 2020, 11, 216-222.	0.6	7
786	Lanthanide-semiconductor probes for precise imaging-guided phototherapy and immunotherapy. Journal of Bio-X Research, 2020, 3, 193-204.	0.3	0
787	Potential Pharmacotherapeutic Phytochemicals from Zingiberaceae for Cancer Prevention. , 2020, , 221-281.		1
788	Radiosensitizers in the Era of Immuno-Oncology. Cancer Drug Discovery and Development, 2020, , 339-360.	0.2	0
789	Cancer immunity and immunotherapy. , 2020, , 471-486.		0
790	Immune Targets in Colorectal Cancer. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 205-230.	0.2	0
791	Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma. Frontiers in Pharmacology, 2021, 12, 757194.	1.6	15
795	Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 68-71.	0.3	0
796	Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial. International Journal of Hematology, 2022, 115, 222-232.	0.7	15
797	Predicting a Kind of Unusual Multiple-States Dimerization-Modes Transformation in Protein PD-L1 System by Computational Investigation and a Generalized Rate Theory. Frontiers in Chemistry, 2021, 9, 783444.	1.8	1
798	Lipid Nanoparticleâ€“mRNA Formulations for Therapeutic Applications. Accounts of Chemical Research, 2021, 54, 4283-4293.	7.6	87
799	Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer. Cancer Immunology Research, 2022, 10, 126-141.	1.6	9
800	CMTM6, a potential immunotherapy target. Journal of Cancer Research and Clinical Oncology, 2022, 148, 47-56.	1.2	7
801	Overexpression of PD-L1 in Papillary Carcinoma and Its Association with Clinicopathological Variables. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 0, , .	0.3	0

#	Article	IF	Citations
802	Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacological Research, 2022, 175, 106019.	3.1	20
803	A Darwinian perspective on tumor immune evasion. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188671.	3.3	6
804	Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression. Tzu Chi Medical Journal, 2022, 34, 1.	0.4	8
805	Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer. Translational Oncology, 2022, 15, 101298.	1.7	7
806	PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?. International Immunopharmacology, 2022, 103, 108484.	1.7	2
807	A Case Report: Internal Carotid Artery Dissection Presenting as Hoarseness Secondary to Vocal Cord Palsy. European Medical Journal Neurology, 0, , 66-71.	0.0	1
808	Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. Frontiers in Immunology, 2021, 12, 719105.	2.2	4
809	Prospects of Immunotherapy for Triple-Negative Breast Cancer. Frontiers in Oncology, 2021, 11, 797092.	1.3	20
810	Nocardia rubra cellâ€wall skeleton influences the development of cervical carcinoma by promoting the antitumor effect of macrophages and dendritic cells. Cancer Medicine, 2022, 11, 1249-1268.	1.3	9
811	Emerging strategies for biomaterial-assisted cancer immunotherapy. Korean Journal of Chemical Engineering, 2022, 39, 227-240.	1.2	1
812	Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing Î³Î´ T cells. Nature Communications, 2022, 13, 231.	5.8	14
813	Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. EBioMedicine, 2022, 75, 103750.	2.7	73
814	First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs, 2022, 36, 137-151.	2.2	6
815	Cilengitide, an Î±vÎ²3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. Bioengineered, 2022, 13, 4557-4572.	1.4	6
816	Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nature Communications, 2022, 13, 816.	5.8	192
817	Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy. Nature Communications, 2021, 12, 7264.	5.8	55
818	MicroRNA-217: a therapeutic and diagnostic tumor marker. Expert Review of Molecular Diagnostics, 2022, 22, 61-76.	1.5	11
819	Anion Receptor-Mediated Multicomponent Synergistic Self-Assembly of Porphyrin for Efficient Phototherapy Elicit ÂTumor Immunotherapy. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
820	Polymeric Systems for Cancer Immunotherapy: A Review. Frontiers in Immunology, 2022, 13, 826876.	2.2	12
821	Immunogenic hydrogel toolkit disturbing residual tumor â€œseedsâ€•and pre-metastatic â€œsoilâ€•for inhibition of postoperative tumor recurrence and metastasis. Acta Pharmaceutica Sinica B, 2022, 12, 3383-3397.	5.7	21
822	Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Acta Pharmaceutica Sinica B, 2022, 12, 3548-3566.	5.7	11
823	Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer. Frontiers in Oncology, 2022, 12, 841977.	1.3	10
824	The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGFâ€Î²2 receptor plus dual checkpoint inhibition maintains antitumor immune cells. Molecular Carcinogenesis, 2022, 61, 549-557.	1.3	6
825	Betulin Attenuates TGF-Î²1- and PGE₂-Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in Mice. Biological and Pharmaceutical Bulletin, 2022, 45, 339-353.	0.6	1
826	Current Clinical Trial Landscape of OX40 Agonists. Current Oncology Reports, 2022, 24, 951-960.	1.8	15
827	Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardio-Oncology, 2022, 8, 3.	0.8	12
828	Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade. Journal of Experimental and Clinical Cancer Research, 2022, 41, 132.	3.5	21
829	An Activatable Polymeric Nanoprobe for Fluorescence and Photoacoustic Imaging of Tumorâ€Associated Neutrophils in Cancer Immunotherapy. Angewandte Chemie - International Edition, 2022, 61, .	7.2	36
830	An Activatable Polymeric Nanoprobe for Fluorescence and Photoacoustic Imaging of Tumorâ€Associated Neutrophils in Cancer Immunotherapy. Angewandte Chemie, 0, , .	1.6	2
831	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	3.2	9
832	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. Translational Oncology, 2022, 20, 101405.	1.7	25
833	A Comprehensive Review of Recent Advancements in Cancer Immunotherapy and Generation of CAR T Cell by CRISPR-Cas9. Processes, 2022, 10, 16.	1.3	13
834	Differentially Expressed Genes in Clear Cell Renal Cell Carcinoma as a Potential Marker for Prognostic and Immune Signatures. Frontiers in Oncology, 2021, 11, 776824.	1.3	7
835	MAPK Activated Protein Kinase 3 Is a Prognostic-Related Biomarker and Associated With Immune Infiltrates in Glioma. Frontiers in Oncology, 2021, 11, 793025.	1.3	3
836	A Review of Emerging Biomarkers for Immune Checkpoint Inhibitors in Tumors of the Gastrointestinal Tract. Medical Science Monitor, 2022, 28, e935348.	0.5	2
837	Chemokines modulate glycan binding and the immunoregulatory activity of galectins. Communications Biology, 2021, 4, 1415.	2.0	5

#	Article	IF	Citations
838	pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition. Frontiers in Immunology, 2021, 12, 794226.	2.2	2
839	Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1). ACS Medicinal Chemistry Letters, 2022, 13, 84-91.	1.3	17
861	Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back. Frontiers in Immunology, 2022, 13, 849515.	2.2	15
862	Oxidative Stress in Cancer Immunotherapy: Molecular Mechanisms and Potential Applications. Antioxidants, 2022, 11, 853.	2.2	10
863	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. Frontiers in Pharmacology, 2022, 13, .	1.6	1
864	Current trends of targeted therapy for oral squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2169-2186.	1.2	23
865	The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development. Advanced Drug Delivery Reviews, 2022, 186, 114316.	6.6	17
866	Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy. Molecular Therapy - Oncolytics, 2022, 25, 236-248.	2.0	9
869	ALTEN: A Highâ€Fidelity Primary Tissueâ€Engineering Platform to Assess Cellular Responses Ex Vivo. Advanced Science, 0, , 2103332.	5.6	3
870	A dual-responsive doxorubicinâ€“indoximod conjugate for programmed chemoimmunotherapy. RSC Chemical Biology, 2022, 3, 853-858.	2.0	1
871	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. Molecules, 2022, 27, 3454.	1.7	5
872	SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	3
873	Combination of OX40 Co-Stimulation, Radiotherapy, and PD-1 Inhibition in a Syngeneic Murine Triple-Negative Breast Cancer Model. Cancers, 2022, 14, 2692.	1.7	11
874	The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. BMC Immunology, 2022, 23, .	0.9	4
875	HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy. Cancers, 2022, 14, 2769.	1.7	8
876	Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review). International Journal of Oncology, 2022, 61, .	1.4	7
877	Beyond GWASâ€"Could Genetic Differentiation within the Allograft Rejection Pathway Shape Natural Immunity to COVID-19?. International Journal of Molecular Sciences, 2022, 23, 6272.	1.8	3
878	Materdicine and Medmaterial. Wuji Cailiao Xuebao/Journal of Inorganic Materials, 2022, 37, 1151.	0.6	6

#	Article	IF	Citations
879	Effects of ginger extract and its major component 6â€gingerol on antiâ€tumor property through mitochondrial biogenesis in CD8⁺ T cells. Journal of Food Science, 2022, 87, 3307-3317.	1.5	8
880	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. Frontiers in Immunology, 0, 13, .	2.2	1
881	Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer, 2022, 3, 665-680.	5.7	18
882	Facts and Hopes in the Relationship of EBV with Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2022, 28, 4363-4369.	3.2	3
883	Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2022, 28, 3590-3602.	3.2	57
884	Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer. Frontiers in Endocrinology, 0, 13, .	1.5	2
885	Targeting breast cancer with a combination of DNT and LAG3 checkpoint blockage and its mechanism. Immunity, Inflammation and Disease, 2022, 10, .	1.3	0
886	Pharmacological Properties of 4â€², 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways. Molecules, 2022, 27, 4304.	1.7	20
887	Self-Activated Cascade Biocatalysis of Glucose Oxidaseâ€“Polycationâ€“Iron Nanoconjugates Augments Cancer Immunotherapy. ACS Applied Materials & Interfaces, 2022, 14, 32823-32835.	4.0	7
888	Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy. Frontiers in Molecular Biosciences, 0, 9, .	1.6	1
889	Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. British Journal of Cancer, 2022, 127, 1584-1594.	2.9	21
890	Pyroptosis-Related Signature as Potential Biomarkers for Predicting Prognosis and Therapy Response in Colorectal Cancer Patients. Frontiers in Genetics, 0, 13, .	1.1	5
891	A tumor microenvironment gene setâ€“Based prognostic signature for non-small-cell lung cancer. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
892	Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. Cancer Immunology Research, 2022, 10, 1190-1209.	1.6	2
893	Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 4012.	1.7	10
894	Immunotherapy in the Treatment of Platinum-Resistant Ovarian Cancer: Current Perspectives. OncoTargets and Therapy, 0, Volume 15, 853-866.	1.0	9
895	Image-guided in situ cancer vaccination with combination of multi-functional nano-adjuvant and an irreversible electroporation technique. Biomaterials, 2022, 289, 121762.	5.7	11
896	Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis. Journal of Immunology Research, 2022, 2022, 1-11.	0.9	2

#	Article	IF	Citations
897	Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Frontiers in Immunology, 0, 13, .	2.2	17
898	The fusion of quantitative molecular proteomics and <scp>immuneâ€oncology</scp>: a step towards precision medicine in cancer therapeutics. FEBS Letters, 2022, 596, 2721-2735.	1.3	4
899	High endothelial venules as potential gateways for therapeutics. Trends in Immunology, 2022, 43, 728-740.	2.9	7
900	Anion receptor-mediated multicomponent synergistic self-assembly of porphyrin for efficient phototherapy to elicit tumor immunotherapy. Nano Today, 2022, 46, 101579.	6.2	9
901	Advances in the biological mechanism and application of manganese-based nanoformulations for enhanced immunotherapy. Nano Today, 2022, 46, 101583.	6.2	8
902	BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression. , 2022, 10, e004859.		12
903	Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines, 2022, 10, 2146.	1.4	0
904	Molecular analysis of Annexin expression in cancer. BMC Cancer, 2022, 22, .	1.1	3
905	Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Review of Clinical Immunology, 2022, 18, 1217-1237.	1.3	7
906	Transcriptome profiles of fatty acid metabolism-related genes and immune infiltrates identify hot tumors for immunotherapy in cutaneous melanoma. Frontiers in Genetics, 0, 13, .	1.1	1
907	Artificial intelligenceâ€driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multiâ€center integration analysis. Molecular Oncology, 2022, 16, 4023-4042.	2.1	13
908	Ferroptosis-related gene ATG5 is a novel prognostic biomarker in nasopharyngeal carcinoma and head and neck squamous cell carcinoma. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	2
909	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
910	PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. Journal of Inflammation Research, 0, Volume 15, 5439-5455.	1.6	1
911	Tumor microenvironment antigens. Seminars in Immunopathology, 2023, 45, 253-264.	2.8	21
912	Firstâ€inâ€human study of <scp>ONO</scp>â€4578, an antagonist of prostaglandin <scp>E₂</scp> receptor 4, alone and with nivolumab in solid tumors. Cancer Science, 2023, 114, 211-220.	1.7	4
913	The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Frontiers in Medicine, 0, 9, .	1.2	6
914	Single-cell analysis reveals nanosecond pulsed electric field ablation induced myeloid cells remodeling in pancreatic cancer. Bioelectrochemistry, 2022, 148, 108266.	2.4	1

#	Article	IF	Citations
915	Platelet-derived TLT-1 promotes tumor progression by suppressing CD8+ T cells. Journal of Experimental Medicine, 2023, 220, .	4.2	14
916	Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy. Cancer Discovery, 2023, 13, 132-145.	7.7	19
917	Plasma TIGIT Level Is a Possible Marker in HIV-Related Liver Damage. Doklady Biochemistry and Biophysics, 2022, 506, 231-236.	0.3	0
918	Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Global Challenges, 2023, 7, .	1.8	3
919	Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-17.	0.5	1
920	Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8+T cells. Cellular Oncology (Dordrecht), 2022, 45, 1297-1309.	2.1	4
921	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. Frontiers in Immunology, 0, 13, .	2.2	3
924	Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer. Frontiers in Immunology, 0, 13, .	2.2	8
925	Stability Convergence in Antibody Coformulations. Molecular Pharmaceutics, 0, , .	2.3	2
926	Adverse events of immune checkpoint inhibitors for patients with digestive system cancers: A systematic review and meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	4
927	Harnessing the Tumor Microenvironment for Cancer Immunotherapy. , 2022, , 1-25.		1
928	Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model. International Journal of Molecular Sciences, 2022, 23, 14073.	1.8	8
929	Targeting Ibrutinib to Tumor-Infiltrating T Cells with a Sialic Acid Conjugate-Modified Phospholipid Complex for Improved Tumor Immunotherapy. Molecular Pharmaceutics, 0, , .	2.3	1
930	Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems in Cancer Case Reports, 2022, 8, 100202.	0.1	0
932	Mechanism and Clinical Application of PD-1/PD-L1 Inhibitors in Immunotherapy. BIO Web of Conferences, 2022, 55, 01007.	0.1	0
933	Endogenous/exogenous stimulies inspired polyprodrug nano-inducer switches pyroptosis path for promoting antitumor immunity. Nano Today, 2023, 48, 101727.	6.2	16
934	LATPS, a novel prognostic signature based on tumor microenvironment of lung adenocarcinoma to better predict survival and immunotherapy response. Frontiers in Immunology, 0, 13, .	2.2	2
935	Recent Advances in Cancer Vaccines: Challenges, Achievements, and Futuristic Prospects. Vaccines, 2022, 10, 2011.	2.1	20

#	Article	IF	Citations
936	Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy. Science Advances, 2022, 8, .	4.7	25
937	Surveying lncRNA-lncRNA cooperations reveals dominant effect on tumor immunity cross cancers. Communications Biology, 2022, 5, .	2.0	4
938	Association between Intratumoral CD8+ T Cells with FoxP3+ and CD163+ Cells: A Potential Immune Intrinsic Negative Feedback Mechanism for Acquired Immune Resistance. Cancers, 2022, 14, 6208.	1.7	2
939	Development of⁸⁹Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. , 2022, 10, e004877.		2
941	High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma. Cells, 2023, 12, 254.	1.8	1
942	Targeted Nanophotoimmunotherapy Potentiates Cancer Treatment by Enhancing Tumor Immunogenicity and Improving the Immunosuppressive Tumor Microenvironment. Bioconjugate Chemistry, 2023, 34, 283-301.	1.8	3
943	The gene signature of tertiary lymphoid structures within ovarian cancer predicts the prognosis and immunotherapy benefit. Frontiers in Genetics, 0, 13, .	1.1	6
944	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. International Immunopharmacology, 2023, 115, 109638.	1.7	3
945	Yin and yang roles of B lymphocytes in solid tumors: Balance between antitumor immunity and immune tolerance/immunosuppression in tumor-draining lymph nodes. Frontiers in Oncology, 0, 13, .	1.3	2
946	Biomaterials tools to modulate the tumour microenvironment in immunotherapy. , 2023, 1, 125-138.		34
947	Injectable Polypeptide Hydrogel Depots Containing Dual Immune Checkpoint Inhibitors and Doxorubicin for Improved Tumor Immunotherapy and Post-Surgical Tumor Treatment. Pharmaceutics, 2023, 15, 428.	2.0	4
948	Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses. Chemical Society Reviews, 2023, 52, 2790-2832.	18.7	28
949	Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression. Tohoku Journal of Experimental Medicine, 2023, , .	0.5	1
950	Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors. Molecules, 2023, 28, 2047.	1.7	1
951	Engineered drug delivery nanosystems for tumor microenvironment normalization therapy. Nano Today, 2023, 49, 101766.	6.2	5
952	Role of exosomes in non-small cell lung cancer and EGFR-mutated lung cancer. Frontiers in Immunology, 0, 14, .	2.2	4
953	Allosteric synthetic antibody (Allo-SyAb) for improved cancer immunotherapy. Chemical Engineering Journal, 2023, 463, 142374.	6.6	2
956	Identification of Gene Signature-Related Oxidative Stress for Predicting Prognosis of Colorectal Cancer. Oxidative Medicine and Cellular Longevity, 2023, 2023, 1-17.	1.9	1

#	Article	IF	Citations
957	Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction. International Journal of Molecular Sciences, 2023, 24, 3971.	1.8	4
958	Smart Oneâ€forâ€All Agent with Adaptive Functions for Improving Photoacoustic /Fluorescence Imagingâ€Guided Photodynamic Immunotherapy. Small Methods, 2023, 7, .	4.6	17
959	Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. Bone Research, 2023, 11, .	5.4	38
960	Singleâ€cell atlas of the immune microenvironment reveals macrophage reprogramming and the potential dual macrophageâ€targeted strategy in multiple myeloma. British Journal of Haematology, 2023, 201, 917-934.	1.2	3
961	Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy. Advanced Materials, 2023, 35, .	11.1	33
962	Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	32
964	Rheumatologic immune checkpoint inhibitor-related adverse events. Current Opinion in Rheumatology, 2023, 35, 141-148.	2.0	2
965	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Molecular Cancer, 2023, 22, .	7.9	32
966	Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration. Cancer Medicine, 2023, 12, 10990-11009.	1.3	4
967	Establishing the applicability of cancer vaccines in combination with chemotherapeutic entities: current aspect and achievable prospects. , 2023, 40, .		0
968	Leveraging Advancement in Robotics in the Treatment of Cancer. Biological and Medical Physics Series, 2023, , 365-404.	0.3	0
969	Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation. Science Advances, 2023, 9, .	4.7	9
970	Biology of Cancer. , 2023, , 86-186.		0
971	Significance of cuproptosisâ€related <scp>lncRNA</scp> signature in <scp>LUAD</scp> prognosis and immunotherapy: A machine learning approach. Thoracic Cancer, 2023, 14, 1451-1466.	0.8	1
984	NK cells direct the perspective approaches to cancer immunotherapy. , 2023, 40, .		0
1000	Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 0, , .	1.3	0
1001	Application and Effectiveness of Chinese Medicine in Regulating Immune Checkpoint Pathways. Chinese Journal of Integrative Medicine, 2023, 29, 1045-1056.	0.7	1
1002	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5

#	Article	IF	Citations
1004	Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors. Medicinal Chemistry Research, 2023, 32, 2089-2115.	1.1	2
1008	Targeting immune checkpoints for cancer therapy. , 2023, , 95-134.		0
1020	Recent advancement of nanomedicine-based targeted delivery for cervical cancer treatment. , 2023, 40, .		0
1022	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: anÂupdatedÂreview. , 2023, 40, .		0
1025	Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech, 2023, 13, .	1.1	0
1031	Responsive biomaterials: optimizing control of cancer immunotherapy. Nature Reviews Materials, 2024, 9, 100-118.	23.3	1
1034	Technological evolution in cancer diagnosis and therapeutics. , 2024, , 33-54.		0
1042	Current status and future prospective of breast cancer immunotherapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0
1057	Synergistic Potential of Antigen-Specific Vaccines and Immunomodulatory Agents for Lung Cancer Treatment. , 2024, , 317-330.		0